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The nervous system is a complex entity that controls from the most basic 
to the most advanced functions known to occur in living organisms. The 
sophistication of the entire nervous system is beyond the scope of this project, 
however, the cholinergic division (i.e. those neurons that release acetylcholine 
and possess receptors that are involved in acetylcholirie neurotransmission) is of 
utmost interest in these studies. 
The cholinergic system exists in both the central and peripheral nervous 
systems. Central aspects of cholinergic activity are involved in learning and 
memory while peripheral cholinergic activity includes both somatic and 
autonomic systems, which form the peripheral nervous system. The autonomic 
system consists of two divisions, the sympathetic and parasympathetic system. 
The former is also referred to as the "fight or flight" system due to its involvement 
in enabling a creature to "stand its ground" or flee, whereas the latter is known 
as the "rest and digest" system and allows an organism to perform essential 
metabolic activity to regain spent strength or recover from daily activities. The 
interesting thing about these divisions of systems is that they fall under the 
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control of a single neurotransmitter, acetylcholine (ACh), and are thus part of the 
cholinergic system (Cooper et al., 1991 ). ACh is not present at the terminals of 
the effector organs in the sympathetic system, but is located in the ganglia 
connecting the post ganglionic nerve cells to the central nervous system thus 
ultimately controlling whether the target organ will receive any catecholamines 
(Taylor, 1990). 
ACh is a ubiquitous compound, present in some of the simplest nervous 
systems. Much evidence about the workings of our own cholinergic system has 
come from studying the same found in animals. Since the first experiments 
performed by Loewi in 1921 in the frog heart showed ACh release controlled by 
nerve stimulation and as will be reviewed and revealed throughout these 
studies, animals were essential in developing and determining cholinergic 
function and its interaction with potential toxicants. 
As mentioned previously, acetylcholine is an important neurotransmitter in 
humans as well as other organisms. To understand better the research 
conducted here, it is important to review the primary pathways of acetylcholine 
synthesis and release, effector systems that respond to acetylcholine and how 
organophosphorus (OP) insecticides may interact with and modulate cholinergic 
activity. The primary molecular players, shown in Figure 1, are 
acetylcholinesterase, adenylyl cyclase (AC), cholinergic receptors, and most 
importantly high affinity choline uptake (HACU). It is important to note here that 
these components of cholinergic signaling will be reviewed in the context of 
general structure and function with reference to how they have been proposed to 
2 
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Figure 1. A general description of the primary components of the cholinergic 
synapse. 
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change with age and interact with OPs, considering this research focuses on 
age-related differences in sensitivity to these compounds. 
Organophosphorus compounds have been in use since the 1930's. 
Developed as nerve agents during World War II, their fourth generation 
derivatives still provide a tool for pest eradication in numerous settings 
(Ecobichon, 2001 ). Approximately 5 billion pounds are produced and applied 
annually throughout the world with about 100 million pounds used in the United 
States (Aspelin, 1997). The potent toxicity of OPs has resulted in their use as 
insecticides. Combined, their extensive use and potency lead to an estimated 5 
million acute poisonings worldwide each year (Lang, 1993), which raises serious 
concerns for potential exposure and vigilant regulation of their use. 
The toxicity of OP compounds was not immediately realized. In fact, it 
was not until 1932, when Lang and Kreuger exposed rats to new organic 
pesticides that a description of the induced toxicity of these compounds was 
recorded. Only 5 years later, in 1937, Gerhard Schrader led his team of 
scientists, to synthesize the first commercially available OP pesticide, 
tetraethylpyro-phosphate {TEPP), at Farbenfabriken Bayer AG (Gallo and 
Lawryk, 1991; Schrader and Kukenthal, 1937). Unfortunately, the toxicity of 
) 
OPs was exploited and nerve gases including soman, sarin and tabun were 
synthesized as potential chemical warfare agents during World War II and such 
military use was realized more recently against the Kurdish during the Iraq-Iran 
War and Persian GulfWar(Ehrich, 1998; Koelle, 1994; Nagao et al., 1997). 
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The use of OPs as insecticides became more prevalent with the synthesis 
of derivatives that had more "desirable" traits including low volatility and 
moderate environmental persistence (chemical stability towards sunlight and 
water). These qualities were found in what is considered the prototypical OP 
insecticide, parathion (PS), which was synthesized in 1944, followed shortly after 
by its highly potent anticholinesterase oxygen analog paraoxon (PO). OPs soon 
replaced the use of organochlorine (OC) pesticides of the 1950s, which resulted 
in a number of fatal poisonings of workers due to the lack of selectivity of PS 
toward target and non-target species compared to the relatively non-toxic and 
familiar OCs (Ecobichon, 2001). This led to the development of OP insecticides 
having greater selective toxicity toward target species (Austin and Berry, 1953). 
One of the most extensively used and studied OP insecticides is chlorpyrifos 
(CPF; Richardson, 1995), because of its relatively low mammalian toxicity and 
desirable lack of environmental persistence (Racke, 1993). The structures of PS 
and CPF are shown in Figure 2. Both are referred to as parent compounds, 
meaning they require metabolic activation via cytochrome P-450 to the potent 
anticholinesterases PO and chlorpyrifos axon (CPO), with oxygen replacing 
sulfur on the phosphorus molecule (Holmstedt, 1963). Presently, after hundreds 
of derivatives and thousands of products, there are 38 OP pesticides under 10 
different chemical classifications registered for use by the Environmental 
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Figure 1. The chemical structures of parathion and chlorpyifos. 
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OP insecticides elicit toxicity by disrupting neuronal pathways involving 
cholinergic nerves. As mentioned above, these pathways are located centrally 
and peripherally and use acetylcholine (ACh) as the primary neurotransmitter 
(Lamour et al., 1990). ACh is synthesized from choline and the cofactor, acetyl 
coenzyme A (CoA), which donates the acetyl group, via the synthetic enzyme 
choline acetyltransferase (ChAT, EC 2.3.1.6). This process takes place in the 
terminal bud of cholinergic neurons. The choline precursor must be transported 
into the nerve terminal via sodium-dependent high affinity choline transport, a 
process that is explained in more detail later and is considered to be the rate 
limiting step in the synthesis of ACh (Kuhar and Murrin, 1978). Acetyl CoA is 
provided by pyruvate formed from glucose metabolism in the inner membrane of 
the mitochondria. Once ACh is formed, it is transported into vesicles located 
near the inner leaflet of the plasma membrane via the membrane bound 
vesicular ACh transporter (VAChT). Upon depolarization of the neuron by an 
action potential, voltage-gated Ca2+ channels open allowing Ca2+ to enter and 
engage a docking mechanism that fuses the vesicle membrane to the inner 
leaflet of the plasma membrane of the nerve terminal. This results in the 
exocytotic release of the vesicle contents into the synapse where ACh can now 
interact with postsynaptic or presynaptic·receptors to propagate the action 
potential of postsynaptic neurons or attenuate the further release of this 
neurotransmitter (i.e. autoregulation; Suzuki et al., 1988). 
Degradation of ACh in the synapse is accomplished by hydrolysis by the 
enzyme acetylcholinesterase (AChE; EC 3.1.1. 7; Quinn, 1987). Aldridge and · 
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Reiner (1972) operationally classified all esterases based on their interaction 
with OP compounds. A-esterases (e.g. paraoxonase, EC 3.1.1.2) can hydrolyze 
(detoxify) OPs without being inhibited (Furlong et al., 1989; Pond et al., 1996), 
8-esterases (e.g. cholinesterases and carboxylesterase, EC 3.1.1.1) will 
stoichiometrically (covalently) bind OPs and become inhibited (Chambers et al., 
1990), and C-esterases do not interact with OPs. The ChEs exist in two forms, 
acetylcholinesterase and butyrylcholinesterase (BChE, EC 3.1.1.8), which are 
more specifically termed serine hydrolases, due to the reaction involving the 
addition of water and an active serine residue. 
Ch Es are widely distributed in tissues of vertebrates and invertebrates. 
To perform its pivotal role in cholinergic neurotransmission, AChE is located in 
the cholinergic synapses throughout the nervous system. AChE is one of the 
most active enzymes in the human body, hydrolyzing up to 80,000 molecules of 
ACh per second. While the physiological role of AChE is well known, the 
function of BChE remains unclear. The cationic nitrogen of ACh is attracted to 
the anionic site of AChE forming the enzyme-substrate complex (Fukuto, 1990). 
This arrangement allows the active site of AChE to access the acetyl group of 
ACh resulting in the acetylated enzyme (i.e. the hydroxyl group of the serine 
residue in the active site of AChE is acetylated), which undergoes deacetylation 
rapidly. The hydrolytic products of ACh, choline and acetate can be recycled 
back into the presynaptic terminal through both low and high affinity membrane 
carriers (Kuhar and Murrin, 1978; Carroll, 1997). 
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It is well documented that the primary mechanism for OP toxicity is 
inhibition of AChE in the central and peripheral nervous systems (Mileson et al., 
1998; Ecobichon, 2001 ). The location of the enzyme as it pertains to inhibition is 
important in the expression of toxicity with OP exposure (Padilla et al., 1994 ). 
Extensive AChE inhibition leads to accumulation of acetylcholine in the synapse 
and consequent over-stimulation of muscarinic and nicotinic cholinergic 
receptors (Silver, 197 4; Aldridge, 1996; Mileson et al., 1998; Sultatos, 1994 ), 
resulting in classic signs of toxicity including excess secretions from the salivary, 
lacrimal, and mucosal glands (i.e. excess salivation, lacrimation, urination, 
defecation, abbreviated SLUD), involuntary movements (e.g. tremors and 
fasciculations), hypothermia (Moser, 1995; Gordon et al., 1997), abnormal heart 
rate (Roberts and Konjovic, 1969), loss of body weight (Pope et al., 1991 ), 
changes in locomotor activity (Moser, 1995; Pope et al., 1992), and a variety of 
other signs (Kaplan et al., 1993; Lotti, 1995). Death from AChE inhibition is 
usually a result of depressed ventilatory control centers in the brain, paralysis of 
the diaphragm and excessive airway secretions (Gupta, 1998; Nostrandt et al., 
1997; Rickett et al., 1986). Some OPs can induce delayed neurotoxicity (Ehrich 
et al.,, 1997). 
ACh released into the synapse binds to presynaptic and postsynaptic 
receptors, which include, as mentioned previously, muscarinic and nicotinic 
types. Muscarinic ACh receptors (mAChRs) are located in the central and 
peripheral cholinergic system and mediate most of the effects of ACh in both 
systems (Buckley and Caulfield, 1992; De Boer et al., 1990). Thus far mAChR 
9 
subtypes have been genetically-defined as m1, m2, m3, m4, and m5 (Bonner et 
al., 1987; Bonner et al., 1988) and their corresponding pharmacologically 
identified subtypes are M1, M2, M3, and M4 based on agonist and antagonist 
binding data (Hulme, 1990; Kenakin et al., 1992; McKinney and Coyle, 1991). 
To date, however, there are no data reporting a pharmacological ligand selective 
for the m5 receptor. Structurally, the mAChRs are classified as a family of 
receptors that when activated by ligand binding undergo a conformational 
change to form a coupling with G-proteins in the cellular membrane. G-proteins 
are heterotrimers of a, J3, and y subunits. This coupling to G-proteins activates 
the alpha (Ga) subunit releasing GDP and binding to GTP along with uncoupling 
of the beta/gamma (13/y). There are multiple subtypes of Ga including Gai, Gaq111 , 
or Gaito, which are coupled to specific mAChR subtypes and determine the 
induction of various responses. Inhibition of adenylyl cyclase resulting in 
decreases in the diffusible second messenger cAMP is a consequence of ACh 
binding to M2 and M4 subtypes coupled to the pertussus toxin-sensitive Gai 
(Birnbaumer etal., 1990; Felder, 1995). Stimulation of phospholipase C with a 
corresponding rise in inositol triphosphate (IP3) and diacylglycerol (DAG) will 
occur when ACh activates M1, M3, and M5 subtypes that are coupled to the 
pertussus toxin-insensitive Gaqt11 (Berstein et al., 1992). Inward rectification of 
potassium channels occurs from the f3/y subunit released from the associated 
Gaito upon M2 and M4 agonism (Kofuji et al., 1995). 
Radioligand binding studies have been used to examine the mAChR 
subtypes. The mAChR antagonist [3H]quinuclidinyl benzilate (QNB) is most 
10 
commonly used to label the total population of muscarinic receptors (Kuhar and 
Yamamura, 1975; Yasuda et al., 1993) and is sometimes compared to [3H]N-
methyl scopolamine (NMS), which only labels muscarinic receptors on the 
membrane surface, to potentially give an estimate of receptor 
internalization/down-regulation. The initial classification of mAChR subtypes 
used another muscarinic antagonist [3H]pirenzapi~e. which is selective for the 
M1 subtype (Hulme et al., 1990; Caulfield, 1993). M2 subtypes can be 
distinguished using the selective antagonists [3H]methoctramine or [3H]AF-DX 
116 and highly selective agonists such as cis-methyl dioxolane (CD; Huff and 
Abou-Donia, 1994; Jett et al., 1991; Ward and Mundy, 1996). The antagonist 
used to identify the M3 subpopulation of mAChR is [3H]4-DAMP (4-
diphenylacetoxy-N-methylpiperidine methiodide; Dorje et al., 1991; Lazareno et 
al., 1990). M4 receptors have recently been distinguished using the antagonist 
[3H]himbacine (Bernheim et al., 1992; Caulfield and Brown, 1991 ). To date, 
there is no selective ligand for the m5 gene product. 
Much of the diversity associated with muscarinic receptors has been 
discovered due to their various functions in modulating molecular mechanisms 
of different cell types within an organism (Eglen et al., 1996). lmmunoreactivity 
studies have shown this diversity based on several regional tissues located in 
the brain as well as the periphery (Levey et al., 1991 ). These receptors have 
been found in the cortex, hippocampus, thalamus, hypothalamus, striatum, pons 
and cerebellum, all regions important in regulating cognition (learning), body 
temperature, emotions (human), and basic unconcious events, such as 
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metabolism and smooth muscle activity (Stillman et al., 1996). Furthermore, 
peripheral locations of muscarinic receptors include glands, heart, vasculature, 
lung, ileum, and sympathetic ganglia. The muscarinic receptor subtypes have a 
greater distribution and concentration in the brain regions compared to the 
periphery, with the m2 subtype present in the regions listed above (for a review 
see Caulfield, 1993). 
Although cholinergic neurogenesis appears to be complete in rats around 
prenatal day 17 (Semba and Fibiger, 1988), development of muscarinic 
receptors has been shown to occur postnatally in rats. Kuhar and coworkers 
(1980) examined the ontogeny of acetylcholine muscarinic receptors in the 
cortex, diencephalon, and the pons-medulla using radiolabeled muscarinic 
selective low (propylbenzilylcholine) and high (oxotremorine) affinity agonists to 
label surface and total receptor populations. One day-old rats had the lowest 
density of muscarinic receptors (5% of adult levels) with 50% being capable of 
high affinity binding. Receptor density reached adult levels by day 20. Likewise, 
Disko and coworkers (1999) have shown that postnatal expression of choline 
acetyltransferase activity, ACh release and muscarinic autoreceptors in the 
septum and hippocampus occurs synchronously beginning as early as postnatal 
day (PND) 3 and increasing to near adult levels (60%) by PND 16. 
In contrast to G-protein coupled (metabotropic) muscarinic receptors, 
nicotinic ACh receptors (nAChR) are ligand-gated (ionotropic) ion channels that 
can consist of 16 possible subunits (a1-a9, f31-f34, y, <> and i::) arranged in a 
pentameric structure around a central ion channel (Barnard, 1992; Karlin and 
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Akabas, 1995; Lindstrom, 1996; Unwin, 1993; Wonnacott, 1997). nAChR allow 
entry primarily to sodium and calcium depending on the particular subunits that 
make up the channel (Albuquerque et al., 1995; Cooper et al., 1991; Castro and 
Albuquerque, 1995). 
The basic subunit composition of a neuromuscular type nAChR consists 
of two a1, one (31, one y and one 8 in neonatal tissues and two a1, one 131, one E 
and one 8 in adult tissues (Galzi and Changeux, 1995; Witzemann et al., 1990). 
Comparatively, the major subunit composition of a central neuronal nAChR 
consists of a4J32 and a7 subtypes (Decker, et al., 1995; Lukas and Eisenhour, 
1996; Holladay et al., 1997; Vidal and Change·ux, 1996). Additionally, the 
ganglionic subunit composition is primarily a3(34 (Vemalis et al., 1993; Badia et 
al., 1997). It is important to note that the functionality of the nAChR is 
dependent on the presence of at least two alpha subunits, which contain the 
ligand binding sites and are responsible for the opening of the ion channel (from 
a closed diameter of 0.7 nm to the open diameter of 2.5 nm). The amino acic::J 
sequence of each transmembrane subunit lining the pore of the channel plays a 
role in the ion selectivity of the channel (Haass and Kubler, 1996). The subunit 
assortment determines the binding properties, ion permeability, time of closure, 
and desensitization rates of the receptor (Fenster et al., 1997; Albuquerque et 
al., 1997). It is well known that nAChR rapidly desensitize during excessive 
agonist exposure (McGehee and Role, 1995; Auerback and Akk, 1998; Booker 
et al., 1998). 
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Just as with the mAChR, radioligands and neurotoxins have been used to 
distinguish different nAChR populations (Swanson and Albuquerque, 1992). 
Agonists for nAChR including [3H]nicotine and [3H]epibatidine are selective for 
the a.4P2 conformation(~= 0.5 - 5.0 nM and 0.79 - 2.1 nM, respectively; 
Flores et al., 1992; Kellar, 1995; Holladay et al., 1997; Houghtling et al., 1995), 
whereas [1251] a.-bungarotoxin is selective for the a.7 subtype (Kd = 0.65-1.7 nM; 
Coutuier et al., 1990; Marks et al., 1986). 
These divisions of ACh receptors, muscarinic and nicotinic, described 
above have been found to exist on both the postsynaptic nerve membrane as 
well as the presynaptic nerve terminal (Vilaro et al., 1994). While activation of 
postsynaptic receptors affects cellular function, the presynaptic receptors are 
coupled to the regulation of neurotransmitter release from the nerve terminal (i.e. 
autoregulation). Presynaptic mAChRs are involved in a negative feedback loop 
to inhibit excess ACh release (Russell et al., 1985). In contrast, although less 
understood, presynaptic nAChRs act through a positive feedback loop and 
enhance neurotransmitter release when bound by an agonist, which would be 
important during impaired cholinergic function (Marchi and Raiteri, 1996). Thus, 
the colocalization of these two types of cholinergic autoreceptors indicates they 
predominate under different conditions. These same receptors can act as 
heteroreceptors regulating the release of transmitter by other neurons. 
Development of the muscarinic autoreceptor and its relationship to 
acetylcholine release in cortical synaptosomes collected from 10, 14, 18 and 30 
day-old rats was studied by Marchi and colleagues (1983). This group reported 
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that calcium-dependent acetylcholine release was present in cortical 
synaptosomes by postnatal day 10, but muscarinic receptor mediated inhibition 
of acetylcholine release (autoregulation) was not detectable until postnatal day 
14 and not fully developed until day 30 (95.7% of adult levels). Recent studies 
suggest muscarinic autoreceptors may be important in the ultimate expression of 
toxicity following exposure to organophosphorous anticholinesterases (Pope et 
al., 1995; Liu et al., 2002) and that their maturational expression may contribute 
to the age-related differences in sensitivity to these agents (Won et al., 2001 ). 
Parathion and chlorpyrifos are two commonly used thiophosphoric acid 
' 
(thiophsophoryl-type) OPs (Pope, 1999). Several studies suggest additional 
macromolecular targets exist for PS and CPF in addition to AChE (Bartels and 
Nachmansohn, 1969; Eldefrawi and Eldefrawi, 1983; Katz et al., 1997; Katz and 
Marquis, 1992; Mourik and de Jong, 1978; Rao et al., 1987). An in vitro study 
(Volpe et al., 1985) reported modulation of muscarinic receptor binding in the 
bovine caudate nucleus by some OPs. Others have noted direct interaction of 
OPs with muscarinic receptors (Abdallah et al., 1992; Sakry et al., 1988; Katz, 
Marquis, 1989; Jett, 1991; Huff and Abou-Donia, 1994; Huff et al., 1994; Sun et 
al., 1994; Van den Beukel et al., 1997). Binding of CD, a high affinity muscarinic 
agonist, can be directly altered by some OPs (Sakry et al., 1988; Ward et al., 
1993). CD has also been shown to label selectively the M2 subtype of 
muscarinic receptor that appears to be concentrated in the presynaptic terminal 
(Huff and Abou-Donia, 1994; Huff et al., 1994; Watson et al., 1986). A recent 
study by Ward and Mundy (1996) reported that paraoxon and chlorpyrifos oxon 
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inhibited forskolin-stimulated cAMP formation in a concentration-dependent 
manner (IC50 = 170 and 56 nM, respectively) in rat cortical slices suggesting that 
the direct regulation of cAMP formation may participate in the differential toxicity 
of OPs. Previous studies from our laboratory (Chadhuri et al., 1993; Pope et al., 
1995; Liu and Pope, 1996) comparing equi-inhibitory doses of parathion and 
chlorpyrifos in adult rats caused differential modulation of [3H]CD binding (i.e. up 
and down regulation by parathion and chlorpyrifos, respectively). We 
hypothesize that changes in these muscarinic receptors may contribute to the 
underlying differences in toxicity between these two agents. Additionally, 
alterations in muscarinic receptors have been implicated in the development of 
tolerance to some OPs (Costa et al., 1982; Schwab et al., 1981 ). Combined, 
these studies suggest that additional targets for OPs exist presynaptically and 
that direct interaction with these sites may modulate neurochemical and 
adaptive changes modifying the toxic outcome of AChE inhibition (Sidell, 1994 ). 
It is important to note that other studies have indicated a lack of effect on 
postsynaptic receptors or modulation of acetylcholine release by some OPs 
(Camara, et al., 1997). 
Several reports have indicated that inhibitors of HACU/acetylcholine 
synthesis (i.e., acetylsecohemicholinium, N-allyl-3-quinuclidinol and HC-3 
congeners) reduce the toxic effects of some OP AChE inhibitors (Buccafusco 
and Aronstam, 1986; Sterling et al., 1988; Cannon et al., 1990). Some OPs 
such as diisopropylfluorophosphate (DFP), soman, sarin and 
dimethyldichlorovinyl-phosphate (DDVP) have also been reported to reduce 
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HACU early after exposure (Kobayashi et al., 1986; Lim et al., 1987; Whalley 
and Shih, 1989). Liu and Pope (1996, 1998) reported that acute chlorpyrifos 
exposure reduced both high affinity choline uptake and [3H]hemicholinium-3 
binding, a specific measure of the choline transport protein (Sandberg and 
Coyle, 1985). These studies combined with the more recent discoveries of 
cAMP modulation by direct OP-muscarinic receptor interaction may provide the 
rationale for the ability of some OPs to modify acetylcholine synthesis. A 
reduction in acetylcholine synthesis could result in less neurotransmitter being 
released into the synapse and consequently, lower toxicity with AChE inhibition. 
High affinity choline transport, the rate limiting step in acetylcholine 
synthesis (Kuhar and Murrin, 1978), has been studied for over 40 years. Birks 
and MacIntosh (1961) reported the presence of a choline carrier while 
investigating the metabolic pathway of ACh in cat sympathetic ganglia. These 
results noted the efficient conversion of choline from the blood into ACh and 
stated that the nerve endings themselves must have "some special 
mechanisms" to transport choline into the nerve cell. Further characterization 
studies in other laboratories (Diamond and Kennedy, 1969; Haga, 1971; 
Marchbanks, 1969) found that this transporter was dependent on sodium and 
that the efficiency of ACh synthesis was greater at lower concentrations of 
choline (in the low µM range). Several workers soon investigated the kinetics of 
choline transport and found two systems present in nervous tissue (Dowdall and 
Simon, 1973; Haga and Noda, 1973; Kuhar et al., 1973; Yamamura and Snyder, 
1973; Yamamura and Snyder, 1974). One had a low affinity for choline (Kr= 
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10-100 µM), was not energy dependent (passive), and was poorly correlated 
with acetylcholine synthesis and regional brain choline acetyltransferase activity 
(ChAT, EC 2.3.1.6), the standard marker for cholinergic nerve terminals. The 
second had a high affinity for choline (KT = 0.5-5 µM), high dependency on 
sodium, activity dependent association with ACh synthesis, and a high 
correlation with regional brain ChAT. The characteristics of the high affinity 
choline transporter accompanied by studies indicating a loss of cholinergic nerve 
terminals results in a reduction of HACU suggest its localization in cholinergic 
nerve terminals (Kuhar et al., 1973; Kuhar et al., 1975; Suszkiw and Pilar, 1976). 
Other studies involving non-neuronal tissues (e.g. muscle) and cholinergic cells 
lacking terminals further support this finding (Pert and Snyder, 197 4; Suzkiw et 
al., 1976). These findings have been confirmed and further described by a 
number of laboratories that have identified the physiological importance of 
sodium-dependent HACU and its necessity in the on-demand synthesis and 
release of ACh (for review see Kuhar and Murrin, 1978). 
The mechanism(s) of regulating HACU have been more elusive to 
determine than the characterization of this important process. Early reports 
indicated synaptosomes from insect ganglia incubated with membrane 
permeable cAMP analogs or phorbol esters could increase HACU and 
[3H]hemicholinium-3 binding, a specific probe for the choline transporter (Breer 
and Knipper, 1990; Knipper et al., 1992). Recent reports indicate HACU is 
regulated by second messenger cascades involving cAMP. Cancela and 
coworkers (1995) reported alterations in HACU in cortical synaptosomes by 
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exogenous cAMP, and by agents that modify cAMP levels (e.g. oxotremorine, 
quinacrine and promethazine). Permeable cAMP analogs increased HACU in 
vitro, while oxotremorine, a muscarinic agonist reduced HACU presumably 
through activation of m2/m4 muscarinic receptors coupled to inhibition of cAMP 
production. Quinacrine and promethazine (a PLA2 and calmodulin inhibitor, 
respectively) reduced HACU and cAMP formation (adenylyl cyclase activity) 
indicating an interaction between these two systems in the regulatory control of 
HACU. More recently, Vogelsberg and coworkers (1997) reported that 
permeable cAMP analogs, forskolin (adenylyl cyclase stimulator), and 
isobutylmethylxanthine (cAMP phosphodiesterase inhibitor) could all increase 
high affinity choline uptake in vivo following intracerebroventricular injection in 
mice. Additionally, okadaic acid, a protein phosphatase inhibitor, increased 
HACU supporting the concept of the choline transporter being a phosphoprotein 
(Salterelli et al., 1987; Chaterjee and Bahtnagar, 1990, Issa et al., 1996). 
If indeed cAMP regulates HACU activity then it is important to understand 
how cAMP levels are regulated. AC is the enzyme responsible for formation of 
cAMP from ATP (Cooper et al., 1995; Sunahara et al., 1996). AC was originally 
discovered in 1971 to be stimulated and inhibited in a GTP-dependent manner 
(Rod bell et al., 1971 a; Rod bell et al., 1971 b; Birnbaumer, 1973; Birnbaumer et 
al., 1974; Yamamura et al., 1977; Londos et al., 1978; Jakobs et al., 1978). 
Subtypes of this enzyme are ubiquitous to all tissues and cell types (Gao and 
Gilman, 1991) and can be influenced in a number of ways, most importantly for 
these studies through its association with G-protein coupled transmembrane 
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receptors. All of the enzyme forms are membrane bound and can be stimulated 
by forskolin. The heterotrimeric G-protein becomes associated with AC when a 
ligand binds to the receptor and the coupled receptor undergoes a 
conformational change. This results in the activation of the specific G-protein 
through the exchange of GTP for GDP, which is bound to the alpha-subunit of 
the G-protein. The now activated G-protein activates AC that will convert ATP to 
cAMP. cAMP acts to regulate a variety of intracellular processes. AC can 
interact with both stimulatory and inhibitory G-proteins (Gs and Gi) leading to its 
activation or inhibition, respectively. 
AC is composed of two cytoplasmic domains, and two membrane-
spanning domains, each containing six transmembrane spans (Cooper et al., 
1995; Sunahara et al., 1996). There is high conservation among subtypes of the 
amino acid sequence, which is thought to contain the nucleotide (ATP) binding 
site. Currently there are 9 isoforms known that are localized differentially 
throughout the regions of the brain. Of these 9 subtypes, four h,ave been tested 
for their differences in expression and activity with age (lhnatovych et al., 2002). 
AC types I, II, IV, and VI as measured in the cortex, thalamus, and hippocampus 
of rats age PND1 - PND90 show a distinct increase (100 - 800%, 100 - 3000%, 
100 - 800%, respectively) in the amount of protein from resolved membranes 
compared to the activity of AC types regardless of protein (by a variety of 
stimulants), which peaks at PND12 and declines to near or less than newborn 
activity in most cases. These differences in expression versus activity could be 
· a result of differential regulation of this enzyme and its role(s) during maturation 
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(i.e. even though the protein is present, this may be a foreboding of the activity 
or lack there of for a particular process that has, is, or will develop). Differences 
in the activities of these isoforms could be important in potential age-related 
effects of a xenobiotic capable of modulating AC activity. 
The developmental aspects of HACU are not well defined. Early studies 
indicated a tight correlation between the development of ACh synthesis and 
choline uptake (Atweh et al., 1975; Jenden et al., 1976; Mathews et al., 1974; 
Murrin and Kuhar, 1976; Polak et al., 197 4; Simon et al., 1976). One study 
investigating the development of cholinergic markers in rat fascia dentata 
reported an age-related increase in HC-3 sensitive HACU, ACh synthesis, ChAT 
activity, and AChE activity from 5-10% of adult levels (3 day-old tissues) and 
rising to 100%, 65%, 30%, and 25% of adult values (30 day-old tissues), 
respectively (Shelton et al., 1979). Studies in human basal ganglia have shown 
that choline transport as determined by [3H]hemicholinium-3 binding is minimal 
in the fetal striatum but increases throughout childhood reaching adult levels 
during late juvenile development (Lowenstein et al., 1987). 
Over the years, our laboratory has studied differences in acute toxicity 
following exposure to two different OPs, namely parathion and chlorpyrifos 
associated with similar changes in AChE activity. These insecticides are 
metabolized through oxidative desulfuration (Soranno and Sultatos, 1992; 
Sultatos et al., 1985; Sultatos and Murphy, 1983) to their respective axons 
(paraoxon and chlorpyrifos-oxon), which are potent inhibitors of AChE (De Neef 
et al., 1983). Upon exposure to maximum tolerated doses (18 mg/kg, sc and 
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280 mg/kg, sc) of each of the parent compounds (parathion and chlorpyrifos, 
respectively), similar degrees of brain AChE inhibition were observed, yet 
noticeably different overt toxicity was noted (Chaudhuri et al., 1993; Pope et al., 
1995; Liu and Pope, 1998; Rainsford, 1978). Correlations of whole blood and 
regional brain AChE levels with functional observations of toxicity were evident 
with parathion exposure, whereas comparisons of clinical indicators of toxicity 
following chlorpyrifos administration were not apparent with several measures 
and had menial correlations (relative to parathion treatment) with AChE 
inhibition. Additionally, CPF in vivo has been shown to decrease HACU in brain 
within 24 hours after subcutaneous exposure in female rats (Liu and Pope, 
1996, 1998), but only later (48 hrs) with PS. Differential expression of toxicity 
following extensive AChE inhibition following PS or CPF may be partially 
explained by OP modulation of choline uptake. The early reduction of HACU by 
CPF may protect the animal from extensive AChE inhibition by decreasing the 
net amount of ACh available in the synapse, thus reducing over-stimulation of 
cholinergic pathways. These studies suggest that neurochemical adaptations 
may occur concurrently with target enzyme inhibition that can modulate the toxic 
consequences of CPF. 
In addition to the recent findings of OP interaction with additional targets, 
age related differences in response to certain OPs have become of great 
concern. The Food Quality Protection Act of 1996 has addressed some of these 
concerns. In most toxicological studies, adult animals have been used to 
evaluate pesticide toxicity. Since children consume proportionately more of the 
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foods that may contain pesticide residues (e.g. fruits and vegetables), it is 
appropriate to evaluate differences in response to OPs between neonatal, 
juvenile and adult rats to model potential subpopulation differences in sensitivity 
(Henry, 1997). This study focuses on the effects of parathion and chlorpyrifos 
on two presynaptic processes, high affinity choline uptake and muscarinic 
receptor-mediated inhibition of adenylyl cyclase, in three different age groups (7, 
21 and 90 day-old) of rats. 
In general, young animals are more sensitive to the acute toxicity of OPs. 
As mentioned before, this has led to new regulations mandating more strict 
control over pesticide usage specifically for the protection of children's health. 
Neonatal rats have been reported to be considerably more sensitive to the acute 
toxicity of both parathion and chlorpyrifos (Benke and Murphy, 1975; Pope et al., 
1991 ). Biotransformation differences play a role in the differential sensitivity 
seen during maturation (Atterberry et al., 1997; Mortensen et al., 1996; 
Mortensen et al., 1998; Morgan et al., 1994). However, little is known about the 
effects of OPs on high affinity choline uptake or cAMP formation in neonatal and 
juvenile animals. Rates of enzyme recovery, OP-selective differences in toxicity, 
and differential muscarinic receptor changes in response to AChE inhibition can 
influence age-related sensitivity to OPs (Liu et al., 1999). Song et al. (1997) 
reported disruptions in multiple steps of the adenylyl cyclase cascade following 
developmental exposures to chlorpyrifos. Modeling of this system in cells 
resulted in similar findings (Song et al., 1998). A study from the same lab also 
revealed decreases in HC-3 binding and choline acetyltransferase activity with 
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repeated postnatal exposures to chlorpyrifos (Dam et al., 1999). Few studies 
have examined the individual or comparative effects of developmental exposure 
to parathion and chlorpyrifos on high affinity choline uptake or the adenylyl 
cyclase signaling pathway (Whitney et al., 1995). 
In summary, OP insecticides are well known to cause toxicity through 
inhibition of AChE. Extensive inhibition of AChE leads to accumulation of ACh in 
the synapse of the cholinergic system and with severe poisonings, death from 
respiratory paralysis. In addition to AChE, these compounds are capable of 
binding directly to cholinergic receptors (muscarinic and nicotinic). In the 
presynaptic nerve terminal, muscarinic autoreceptors are G-protein linked 
receptors that, upon stimulation, inhibit adenylyl cyclase activity leading to 
decreases in cAMP formation and are capable of regulating neurotransmitter 
release (Raiteri et al., 1984). cAMP has been reported to proportionately 
regulate HACU. Any change in HACU could translate into a decrease in ACh 
synthesis and release and, ultimately, the amount of ACh in the synaptic cleft 
following AChE inhibition. We hypothesise that OPs bind to muscarinic 
presynaptic autoreceptors causing inhibition of cAMP formation and consequent 
reduction of HACU activity, which may modify ACh synthesis and thus the toxic 
consequences of AChE inhibition. 
The recent concerns over age related sensitivity to pesticides warrants 
the comparison of toxicity in different age groups. There is an expected degree 
of age-related differences with respect to cAMP formation and HACU in the 
younger animals due to lesser amounts of adenylyl cyclase, choline transporter 
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and lower density of muscarinic receptors. This research focused on the ability 
of parathion and chlorpyrifos or their oxons to alter HACU and cAMP levels in 
neonatal, juvenile, and adult Sprague-Dawley rats. 
This project investigated the following specific aims to examine if PS 
and/or CPF, along with their oxons, could modulate cholinergic toxicity by age-
dependently altering HACU and contribute to the age-related differences in 
sensitivity typically associated with these compounds. The specific aims were: 
1. to compare acute sensitivity (lethality) to two OPs (parathion and 
chlorpyrifos) after oral administration in 7, 21, and 90 day-old rats. 
2. to assess the effects of modulation of HACU on expression of OP toxicity. 
3. to examine the effects of paraoxon and chlorpyrifos oxon on high affinity 
choline uptake and cAMP formation in vitro in the frontal cortex and 
striatum of neonatal (7 days old), juvenile (21 days old), and adult (90 
days old) rats. 
4. to investigate in vivo age-related differences in modulation of choline 





Parathion (0,0-diethyl 0-4-nitrophenyl phosphorothioate, PS), paraoxon 
(0,0-diethyl 0-4-nitrophenyl phosphate, PO), chlorpyrifos (0,0-diethyl 0-3,5,6-
trichloro-2-pyridinyl phosphorothioate, CPF) and chlorpyrifos oxon (0,0-diethyl 
0-3,5,6-trichloro-2-pyridinyl phosphate, CPO) were purchased from Chem 
Service, West Chester, PA, and were at least 98% pure (as determined by IR, 
TLC, and GC/FID). These chemicals were stored desiccated under nitrogen at 
4°C with exception of CPO, which was stored desiccated under nitrogen at-
200C. 
Acetylcholine iodide [acetyl-3H], specific activity 73.9 Ci/mmol; adenine 
[methyl-3H], specific activity 35 Ci/mmol; hemicholinium-3 diacetate salt [methyl-
3H], specific activity 124.7 Ci/mmol; and choline chloride [methyl-3H], specific 
activity 75.0 Ci/mmol, were purchased from Dupont New England Nuclear, 
Boston, MA. Acetylcholine iodide, choline ([2-hydroxyethyl]trimethyl ammonium) 
chloride, atropine sulfate, carbamyl choline, oxotremorine, cis-methyl-dioxolane, 
bovine serum albumin (BSA), 2,5-diphenyl oxazole, 1-4-bis [5-phenyl-2-
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oxazolyl]benzene, ethylene diamine tetra acetic acid (EDTA), Triton X-100, Folin 
& Ciocalteu's Phenol Reagent (2.0 normal), acidic alumina (type WA-1), and 
polyethylenimine (50% w/v) were purchased from Sigma Chemical Company. 
Acetylcholinesterase (Type V-S) purified from electric eel was purchased from 
Sigma Chemical Company as a lyophilized powder (1070 units per mg protein) 
and resuspended in 50 mM potassium phosphate buffer (pH 7.0) at 500 units 
per ml. Forskolin (7!3-deacetyl-7!3-[y-N-methylpiperazino]-butyryl-forskolin) was 
purchased from Calbiochem, San Diego, CA. All other chemicals were reagent 
grade. 
Animals 
Neonatal (7 days of age), juvenile (21 days of age) and adult (90 days of 
age) Sprague-Dawley rats (average body weight approximately 15, 50 and 300 
g, respectively) were used throughout these studies. Both sexes were used for 
neonatal and juvenile studies while only males were used for adult studies. 
Adult male and untimed pregnant female rats were purchased from Harlan 
Sprague-Dawley, Indianapolis, IN, and were housed individually in clear 
polycarbonate cages with sanitary pine chips for bedding and given ad libitum 
access to food (Teklad, Madison, WI) and water. The date of birth (postnatal 
day 0, PNDO) was recorded. On PND2, the pups were pseudo-randomized to 
10 pups/dam (where possible, numbers of males and females with each dam 
were equalized), and identified with permanent ink on the appendages. All 
animals were maintained on a 12 hour light:dark illumination cycle. For all in 
27 
vivo OP exposures, rats were given a minimum acclimation period of 5 days 
after delivery before treatment. All procedures involving animals were in 
accordance with protocols established in the NIH/NRC Guide for the Care and 
Use of Laboratory Animals and were reviewed and approved by the local 
Institutional Animal Care and Use Committee. 
Observations of Functional Signs of Cholinergic Toxicity 
One, two, four, twenty-four and ninety-six hours after treatment with PS or 
CPF, rats were weighed, observed and scored for overt signs of toxicity (i.e., 
salivation, lacrimation, urination, and defecation [SLUD] and involuntary 
movements) using the grading scales described below (modified from Moser et 
al. 1988). SLUD was scored as: 1, none; 2, sltght: one symptom or very mild 
multiple symptoms; 3, moderate: multiple symptoms: 4, severe: multiple severe 
SLUD signs. Scoring for involuntary movements was reported as: 1, repetitive 
movements of mouth and jaws; 2, normal quivering of vibrissae, head and limbs; 
3, mild fine tremor, seen typically in the forelimbs and head; 4, severe whole-




The first phase of this project was to estimate the acute lethality of 
parathion and chlorpyrifos in neonatal, juvenile, and adult rats. Acute lethality 
curves for PS and CPF were established for each of the age groups. The 
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curves were used to estimate lethal doses that caused specific percentages of 
death (e.g. LD10 = lethal dose causing 10% death) in these groups. Parathion 
and chlorpyrifos were dissolved in peanut oil (vehicle) and administered via oral 
gavage feeding needle (straight, 22 gauge x 1" with a 1.25 mm ball for 7 and 21 
day-old and curved, 16 gauge x 4" with a 3.0 mm ball for 90 day-old) to 7, 21, 
and 90 day-old rats. The rats were held by the nape of the neck and the gavage 
tube was inserted into the oral cavity and down the back of the esophagus until 
the shaft ofthe needle was no longer visible. For the dosing regimen, 7, 21, and 
90 day-old rats were challenged with one of a series of dosages of PS or CPF, 
depending on age (neonates, 0.1 - 5 or 3 - 100 mg/kg; juveniles, 0.5 - 10 or 1 O -
210 mg/kg; adults, 1 - 20 or 120 - 400 mg/kg, respectively; n = 6 -
11/dosage/age group) as reported by Zheng et al. (2000). Lethality was 
recorded over a period of 7 days and estimates were tabulated from these 
cumulative values. The respective LD10 and 0.5 x LD10 estimates were used for 
the in vivo experiments throughout most of this project, with the exception of the 
interactivestudies, which.used 0.5, 0.75, and 1 x LD1 estimates. The equation 
used to derive the lethality estimates was: 
Equation 1: Y = ((0- 100)/(1 + (X/LD5o)"b)) + 100 
This equation was derived with the help of Dr. David Roane at the 
University of Louisiana and used in the computer graphing and analysis software 
"GraphPad Prism" from Graph Pad Software, Inc. This equation is a simple 
nonlinear regression line to fit sigmoidal shaped dose-response data and 
estimate Y (level of response in percent) from the given X (range of doses of 
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insecticide used, mg/kg). The variable LD50 can be changed to predict any LDxx 
value with a predefined estimated Hill slope (b). The values of O and 100 
represent opposite ends of the spectrum of responses in percent that may occur. 
lntracerebroventricular Surgery and Injections 
Adult rats were anesthetized with pentobarbital (50 mg/kg as 1 mg/ml in 
saline, i.p.) using a 1 cc syringe with a 24-gauge needle. Anesthesia was 
usually reached by 20 minutes, otherwise a supplemental injection of 20 per 
cent of the original dose was given. Atropine sulfate (0.5 mg/kg, i.p.) was given 
to minimize salivary secretions and keep the airway open during the procedure. 
Once the rat lost reaction to tail-pinch, the scalp was shaved from the 
base of the neck to between the eyes and from ear to ear using hair clippers. 
The rat was then placed in a Stoelting stereotaxic apparatus. The tightened ear 
bar was placed in the external auditory meatus of the respective ear and head 
facing the incisor bar. Then the other ear bar was moved into place to attain a 
snug fit to keep the head from moving side-to-side and tightened, ensuring that 
the head was centered. The upper incisors were placed over the incisor bar and 
the nose clamp tightened. 
The scalp was then swabbed with gauze moistened with 70% ethanol. A 
midline incision was made in the scalp spanning from the edge of the center of 
the eyes to just behind the ears. Four hemostats were used to pinch the four 
edges of the skin and pull it back and hold it in place. The scalpel blade was 
used to scrape the connective tissue covering the skull. The incised area was 
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cleaned of residual blood and tissue using cotton swabs. Bregma, the fissure of 
saggital and coronal sutures, was located and identified as the point where the 
coronal and saggital sutures meet. Lambda was located and identified as the 
point where the lambdoidal and saggital ·sutures join. These reference points 
were used to ensure proper skull alignment and tilt. This was used as the 
reference point to locate the area for the drill to place a hole for the cannula. 
Using the rat brain stereotaxic atlas (Paxinos and Watson, 1986) to determine 
the appropriate coordinates, the drill was moved back (A:P) 1 mm and to the 
right (M:L) 1.5 mm. The drill was lowered to the skull until bone shavings 
appeared and then lowered an additional 0. 75 mm (approximate thickness of the 
skull). Two holes were then drilled for the anchor screws to the same depth but 
positioned only approximately to the left and right of the saggital suture. 
Using the stereotaxic apparatus, the cannula guide was placed in the 
lateral (3rd) ventricle and then the anchor screws were inserted with a butterfly 
screwdriver. Dental cement was mixed and applied over the anchor screws and 
around the cannula guide and allowed to dry for 10 minutes. The rat remained 
in the apparatus until the cement was dry then the dummy cannula was firmly 
attached to the cannula guide and the rat was pl~ced in a polycarbonate cage 
under a small incandescent lamp (for warmth) to recover for about 30 minutes. 
lntracerebroventricular injections of hemicholinium-3 (10, 20 and 50 mg in 
5 µI saline) were given using a 10 µI gastight syringe with 20 cm of teflon tubing 
fastening the needle to the cannula (3.5 mm in length) to adult male Sprague-
Dawley rats 30 minutes after exposure to paraoxon (1, 2 and 4 mg/kg in peanut 
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oil, p.o.). Lethality and overt signs of toxicity were recorded at 1, 2 and 4 hours 
then daily for 4 days. At the end of the study, i.c.v. injections of Evans blue were 
given to ensure proper placement of the cannula guide into the lateral ventricle. 
Successful cannulation into the lateral ventricle was estimated at 94% (47/50). 
In Vivo Treatments for High Affinity Choline Uptake Measurements 
Neonatal, juvenile, and adult (7, 21, and 90 days old) rats were treated 
orally with 0, 0.5, or 1 times the respective LD10 of CPF (neonatal=15; 
juvenile=4 7; adult=136 mg/kg) or PS (neonatal=0.8; juvenile=4.1; adult=6.6 
mg/kg) dissolved in peanut oil (vehicle). Animals were weighed and graded at 4, 
24 and 96 hours after treatment and contemporaneous controls were used in all 
cases. At the time of sacrifice, frontal cortex and striatum were dissected and 
HACU and AChE activity and protein content were examined in brain 
synaptosomes prepared from the frontal cortex and striatum at 4, 24, and 96 
hours after exposure. 
Biochemical Assays 
Tissue preparation 
Rats were sacrificed by decapitation at 4, 24 and 96 hours after 
treatment. Whole blood was collected in eppendorf tubes containing heparin 
(200 units; 10,000 units/ml) and centrifuged in a Marathon 13K/M benchtop 
centrifuge (Fisher Scientific, Hampton, New Hampshire) at 1000 x g to obtain 
plasma. The frontal cortex and striatum were rapidly dissected on ice as 
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described by Glowinski and Iversen (1966) and placed in eppendorf tubes and 
stored at -70 °C until the day of assay. In some cases, the diaphragm was also 
collected. On the day of assay, tissues were thawed, weighed and diluted 
(plasma 1 :5; frontal cortex 1 :1 O; striatum 1 :30; diaphram 1 :30) in a potassium 
phosphate buffer (KP04; pH=7.4) in 7 ml polycarbonate centrifuge tubes on ice. 
Tissues were then homogenized on ice using a Polytron PT 3000 homogenizer 
(28,000 rpm for 20 seconds; Brinkmann Instruments, Westbury, NY) and 
homogenates maintained on ice until time of assay. In some cases, tissues 
were further diluted for optimal activity. 
Preparation of Crude Synaptosomes 
Synaptosomes were prepared from fresh tissue (i.e. the day of the assay 
was also the day of sacrifice). Freshly dissected frontal cortex or striatum were 
placed in 7 ml polycarbonate centrifuge tubes, weighed and diluted (1 :30, w/v) in 
Krebs-Ringer buffer 1 (KRB 1; pH 7.4 at 25°C) containing the following salts: 120 
mM NaCl, 5.0 mM KCI, 1 mM MgS04, 1 mM KH2P04, 3.0 mM CaCl2, 10 mM D-
Glucose and 30 mM NaHC03, the two latter compounds were added to the 
buffer on the day of the assay. Homogenates of frontal cortex and striatum were 
prepared on ice with either a Dounce glass-on-glass hand-held homogenizer (10 
strokes, with up/down counting as one stroke). The particulate fraction (P1) was 
produced by low speed centrifugation (1,000 x g for 10 minutes) in a Beckman-
Coulter Avanti J25i centrifuge then resuspended in fresh KR buffer in the 
Dounce homogenizer and spun at 17,000 x g to obtain the second pellet (P2), 
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crude synaptosomes, which were resuspended in the original volume for 
measurement of HACU and AChE activity. 
Membrane Preparation 
Membranes of the frontal cortex and striatum were prepared from frozen 
(-70 °C) samples that had been collected no longer than 3 months prior to the 
assay. Brain regions were thawed then weighed and diluted (1 :20, w/v) in 50 
mM Glycyl-glycine buffer (GGB) containing 200 mM NaCl (pH=7.8) in 7 ml 
polycarbonate centrifuge tubes. Tissues were then homogenized on ice using a 
Polytron PT 3000 homogenizer (28,000 rpm for 20 seconds; Brinkmann 
Instruments, Westbury, NY) and centrifuged for 10 minutes at 48,000 x g. The 
supernatant was discarded and membranes washed once more with fresh 
buffer. The final pellet was homogenized for the third time and immediately 
used for assay. 
High Affinity Choline Uptake 
Crude synaptosomes from brain regions were prepared as described 
above and stored in pellet form until immediately prior to assay. The pellet was 
then resuspended in fresh KRB1 (fully oxygenated by bubbling 95%:5% 02:C02 
gas continuously during assay) in a Dounce glass on glass hand held 
homogenizer using 10 strokes. 
Culture tubes (13 x 100 mm) were placed in plastic coated steel wire 
holders on ice with the number matching the number of samples to be analyzed 
(usually 48 tubes). Tritiated "hot" choline. chloride was defrosted to equilibrate to 
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room temperature under the fume hood then immediately returned to the -70° 
freezer after use. "Cold" (non-radioactive) choline chloride was prepared as a 
36.57 mM solution and serially diluted 3 times (1: 10), with the final dilution 
(36.57 µM) being added to the substrate working reagent. The hot substrate 
consisted of 15 µI of [3H] choline chloride, 200 µI of 36.57 µM cold choline 
chloride, and 385 µI of KR buffer resulting in a final concentration of 0.5 µM hot 
choline chloride substrate and was stored on ice until the beginning of the 
reaction. Once all the assay reagents were prepared, tissues were added to the 
assay tubes, vortexed, and preincubated for 11 minutes at 30°C in a 
reciprocating water bath (model 66800 Precision Scientific, Winchester, VA), 
after which the muscarinic agonists were added (for in-vitro studies, see below) 
in a 50 µI volume addition and the buffer volume adjusted to compensate. Hot 
substrate was then added and tissues were incubated for an additional 5 min to 
allow for [3H]choline accumulation in the synaptosomes. Tubes were assembled 
in replicates of 4 with duplicates for the 30°C incubation and duplicates for a 0°C 
incubation, which accounted for total accumulation and non-specific binding, 
respectively. Specific choline uptake was calculated as the difference between 
30°C and 0°C incubations. 
Choline uptake was stopped by dilution with 3 ml of ice-cold isotonic 
choline chloride and immediate negative pressure filtration with isotonic choline 
chloride onto Brandel GF-C glass fiber filter paper using a Brandel model M-24 
(Biomedical Research and Development Labs, Gaithersburg, MD) receptor 
harvester. The filter paper was then removed and each filtered sample was 
35 
separated from the filter strip and placed in a 7 ml borosilicate scintillation vial 
and 5 ml of Fisher Scinti-Safe scintillation cocktail was added. Filters were 
soaked overnight (approximately 12 hours) and counted in a Wallac Liquid 
Scintillation Counter (Model 1409 DSA, PerkinElmer, .Inc., Boston, MA). 
For in-vitro studies, naive rats (7, 21, and 90 days old) were sacrificed 
and the frontal cortex and striatum dissected to evaluate the effects of carbachol 
and oxotremorine on HACU in each age group. Various concentrations of 
carbachol and oxotremorine (1 µM-10 mM) were used to establish an inhibition 
curve for HACU. 
[3H]Hemicholinium-3 Binding 
[3H]Hemicholinium-3 was used as a specific probe to estimate the density 
of choline transporters essentially by the method of Sandberg and Coyle (1985). 
Washed membranes (100-200 µg protein) were incubated with 
[3H]hemicholinium-3 (20 nM final concentration) in the presence or absence of 
cold hemicholinium-3 (to account for non-specific binding) in GGB at 25°C for 45 
minutes then filtered under reduced pressure over Brandel GF-C glass fiber filter 
paper and washed with ice cold GGB (3 ml, 3 x). Filter papers were presoaked 
in a mixture of 0.5% bovine serum albumin (BSA) and 0.1 % polyethyleneimine 
(PEI) to limit nonspecific binding to filter paper. Filter circles were placed in 7 ml 
scintillation vials and 5 ml Fisher Scinti-Safe scintillation cocktail was added and 
the vials were allowed to stand overnight and then counted for 2 min in a Wallac 
Liquid Scintillation Counter (Model 1409 DSA, PerkinElmer, Inc., Boston, MA). 
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Determination of Forskolin Stimulated cAMP Formation 
Forskolin stimulated cAMP formation was assayed radiometrically as 
described by Ward and Mundy (1996). Preliminary experiments were performed 
to determine appropriate tissue concentrations and incubation time for linear 
rates of cAMP formation. Naive male Sprague-Dawley rats were sacrificed by 
decapitation and the frontal cortex and striatum were dissected and sliced (300 
µm thick) using a Mcllwain tissue chopper (The Mickle Laboratory Engineering 
Co. LTD., Gomshall Surgery, England). Slices (approximately 200 mg wet 
weight) were placed in 50 ml polycarbonate round bottom centrifuge tubes 
containing 20 ml of Krebs-Ringer buffer 2 (KRB2; 118 mM NaCl, 4. 7 mM KCI, 
1.18 mM KH2P04, 1.18 mM MgS04, 24.8 mM NaHC03, 10 mM glucose, and 
0.75 mM CaCl2; pH 7.4). The tubes containing buffer and tissue were placed in 
a gas evaporation tube holder situated in a water bath and washed 3 x for 10 
min each at 35°C for equilibration. 0 2:C02 (95%:5%) gas was bubbled 
continuously throughout the assay. The bubbling was just vigorous enough to 
agitate the slices and keep them circulating in the buffer. After the prewash, the 
slices were labeled for 45 min in KRB2 containing [3H]adenine (30 µCi/20 ml; 
final concentration of 41 nM) at35°C. Following radiolabel incorporation, the 
slices were washed 3 times in 10 ml fresh HEPES-KRB2 and resuspended in 
HEPES-KRB2 buffer (30 mM HEPES, 122 mM NaCl, 4.9 mM KCI, 1.2 mM 
MgS04, 0.75 mM CaCl2, 3.6 mM NaHC03, 11 mM glucose, pH 7.0) containing 
3-isobutyl 1 methylxanthine (IBMX, 1 mM). 
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Aliquots (50 µI, 40-60 mg protein) of slices were transferred to smaller 
polypropylene centrifuge tubes (12 x 75 mm) and forskolin (FSK, 30 µM final 
concentration) was added to activate adenylyl cyclase (AC). Carbachol (100 
µM), oxotremorine (100 µM) or one of a range of concentrations of PO or CPO 
(1 nM~1 mM) were then added to the tissues followed by incubation for 15 
minutes (35°C). In some cases atropine (10 µM) was added to define muscarinic 
receptor specificity. The reactions were terminated by the addition of HCI (1.3 M, 
50 µI). Tubes were vortexed and then centrifuged for 8 minutes at 3000 x g and 
a sample (200 µI) of the supernatant was separated on acidic alumina columns 
for estimation of cAMP. Samples were washed with 8 mis 0.005 N HCI and then 
eluted with 3 mis 0.1 N ammonium acetate. One ml of eluted sample was 
counted to determine cAMP formed. 
Cholinesterase Assay 
Cholinesterase activity was assayed radiometrically as described by 
Johnson and Russell (1975) using a final concentration of 1 mM 
[3H]acetylcholine iodide. Preliminary experiments were performed on control 
tissues to determine incubation time. and tissue concentration necessary for 
linear rates of substrate hydrolysis. The assays were performed in 7 ml 
scintillation vials at room temperature. Reaction mixtures consisted of 60 µI of 
1% Triton X-100 (in 50 mM potassium phosphate buffer, KP04, pH 7.0), 20 µI of 
homogenate and 20 µI of radiolabeled substrate (in 50 mM KP04). The 
substrate was added at staggered intervals to start the incubations and the 
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reactions were stopped at staggered intervals with 100 µI of AChE "stop 
solution". The stop solution consisted of water containing 9.45% chloroacetic 
acid, 2.0% sodium hydroxide, and 11.6% sodium chloride. 
Following termination of the reactions, 5.0 ml of toluene-based 
scintillation cocktail were added and the vials were capped and immediately 
vortexed for 10 seconds. Vials were then counted in a Wallac Liquid Scintillation 
Counter (Model 1409 DSA, PerkinElmer, Inc., Boston, MA). Blanks (i.e., 
reactions with no tissue) were also run to allow correction for non-enzymatic 
hydrolysis of the substrate. Reactions with AChE isolated from the electric eel 
were used to indicate maximal substrate hydrolysis. For brain regions, enzyme 
activity was measured in the synaptosomes prepared for HACU assays and 
related to total protein content, and calculated as cpm per minute incubation per 
milligram of protein. 
Preparation of [3H]Acetylcholine Iodide Substrate 
The radiolabeled substrate was prepared by suspending 1 mCi of 
acetylcholine iodide [acetyl-3H] in 2 ml of 50 mM KP04 (pH 7.0). Working stock 
solutions of substrate (0.63 mM) were prepared by combining 475 µI of 
radiolabel with 94.525 ml of 4.68 mM nonradiolabeled acetylcholine iodide in 50 
mM KP04. This solution was separated into 1.0 ml aliquots and stored at -70°C 
until time of assay. 
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Preparation of Scintillation Cocktail 
Scintillation cocktail consisting of 0.5% (w/v) 2,5-diphenyl oxazole (PPO), 
0.03% (w/v) 1,4-bis[2-(5-phenyloxazolyl)]benzene (PO POP), and 10% (v/v) 
isoamyl alcohol in toluene was prepared in approximately 4000 ml quantities. 
20.0 g of PPO, 1.2 g of POPOP, 400 ml of isoamyl alcohol, and 3600 ml of 
toluene were combined in a 4-L container. The mixture was then stirred 
overnight with a magnetic stirrer until a clear solution was obtained. 
Tissue Protein Estimation 
The total protein content of the brain regions was measured to normalize 
tissue preparations by the method of Lowry et al. ( 1951) using BSA as a 
standard. Aliquots (1 ml) of BSA (1 mg/ml in water) were prepared in advance 
and stored at-70°C. For each assay a standard curve was prepared with 0, 10, 
25, 50, 75, and 100 µg BSA per reaction in duplicate. Standard curve reaction 
mixtures consisted of BSA and KR buffer, which was added at a volume equal to 
the tissue volume in the sample reactions. The final volume was adjusted to 200 
µI with water. The sample reaction mixtures (200 µI) consisted of tissue and 
water. The amount of tissue added depended on the specific dilution and was 
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adjusted such that the total protein content would fall within range of the 
standard curve. Two ml of "Reagent 1" were added and each tube was 
immediately vortexed and allowed to stand for ten minutes at room temperature. 
Two hundred µI of "Reagent 2" were then added, the tubes were vortexed and 
allowed to stand for thirty minutes at room temperature. The absorbance was 
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read at 720 nm using a Beckman UV-VIS Spectrophotometer (Beckman-Goutier, 
Fullerton, CA). 
Preparation of Reagents 1 and 2 
Reagent 1 was prepared immediately prior to assay by combining 1 part 
0.5% copper sulfate (in water), 1 part sodium potassium tartrate (in water), and 
100 parts 2% sodium carbonate in 0.1 N sodium hydroxide. Stock solutions of 
copper sulfate, sodium potassium tartrate, and sodium carbonate in sodium 
hydroxide were prepared in advance and stored at 4°C. Reagent 2 was 
prepared immediately prior to assay by combining equal volumes of Folin's 
Phenol Reagent and water. 
Data Analysis 
Acetylcholinesterase activity, high affinity choline uptake, cAMP 
formation, and hemicholinium-3 binding values were reported as mean ± 
standard error (SE) and were analyzed for significance by one-way analysis of 
variance (ANOVA) and Student-Newman-Keuls (SNK) all-pairwise multiple 
comparisons. SLUD and IM data were reported as median± interquartile range 
(IQR) and were analyzed by Kruskal-Wallis ANOVA and Dunn's multiple 
comparison. The JMP Statistical Package and GraphPad Prism Software were 





Lethality in Neonatal, Juvenile, and Adult Rats Following Acute Exposure 
to Parathion or Chlorpyrifos 
Exposure to high, acute oral doses of parathion resulted in lethality in 
neonatal, juvenile and adult rats. Table 1 shows the peak times to show SLUD 
and IM associated with oral exposure to PS or CPF in 7, 21 and 90 day-old rats. 
Table 2indicates the peak times to lethality associated with oral exposure to PS 
or CPF in each age group. Figure 3 shows the cumulative (7 day) lethality 
associated with a range of doses of PS in neonatal rats. The less toxic CPF was 
also given in multiple doses and the lethality is shown in Figure 4. The dose 
response curve for the lethality of PS and CPF is shown in Figures 5 and 6 with 
each compound exhibiting greater lethality with lower dosages in younger 
animals. Similarly, the curves associated with the lethality of PS and CPF in 
adult rats are present in Figures 7 and 8. The cumulative lethality estimates for 
parathion and chlorpyrifos are summarized in Table 3. Table 4 shows the 
effects of HC-3 or Oxotremorine on PO and CPO lethality. 
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Age Parathion Chlorpyrifos 
Neonates 4 4 
Juveniles 4 24 
Adults 4 48 
Table 1. Time (hours) to peak incidence of functional toxicity associated with 
oral exposure to PS or CPF in neonatal, juvenile, and adult rats. Functional 
signs of cholinergic toxicity (excess SLUD and IM) were scored at 1, 2, and 4 
hours and then daily for 7 days in 7, 21, and 90 day-old rats. Peak signs after 
PS treatment occur at relatively the same time in all age groups tested. 
Comparatively, signs of toxicity following CPF exposure peak earlier in neonates 
and juveniles compared to adults. 
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Age Parathion Chlorpyrifos 
Neonates 4 24 
Juveniles 1 24 
Adults 2 72 
Table 2. Time (hours) to peak incidence of lethality associated with oral 
exposure to PS or CPF in neonatal, juvenile, and adult rats. The lethality of PS 
and CPF was recorded daily for 7 days (168 hours) in 7, 21, and 90 day-old rats. 
Peak lethality after PS treatment occurred earliest in juveniles, followed by 
adults and later by neonates. In contrast, lethality following CPF exposure 
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Figure 3. Cumulative lethality in 7 day-old rats following parathion (PS) 
exposure. Lethality was recorded daily and shown as the percent cumulative 
lethality after 168 hours (7 days). Rats (n = 10-20 I dosage) were treated with 
PS (0.2, 0.5, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.7, and 2.0 mg/kg, po) and 
graded for functional changes at 1, 2, and 4 hours and then daily for 7 days. 
LD10 estimates are based on a convergence of a sigmoidal dose-response 
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Figure 4. Cumulative lethality in 7 day-old rats following chlorpyrifos (CPF) 
exposure. Lethality was recorded daily and shown as the percent cumulative 
lethality after 168 hours (7 days). Rats (n = 10-20 I dosage) were treated with 
CPF (3.0, 7.5, 12.0, 16.5, 17.5, 20.0, 21.0, 22.5, 25.5, 27.5, 30.0, 32.5, 35.0, and 
37.5 mg/kg, po) and graded for functional changes at 1, 2, and 4 hours and then 
daily for 7 days. LD10 estimates are based on a convergence of a sigmoidal 
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Figure 5. Cumulative lethality in 21 day-old rats following parathion (PS) 
exposure. Lethality was recorded daily and shown as the percent cumulative 
lethality after 168 hours (7 days). Rats (n = 10-20 I dosage) were treated with 
PS (0.0, 0.5, 0.8, 1.0, 1.1, 1.4, 1.7, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, and 10.0 mg/kg, 
po) and graded forfunctional changes at 1, 2, and 4 hours and then daily for 7 
days. LD10 estimates are based on a convergence of a sigmoidal dose-
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Figure 6. Cumulative lethality in 21 day-old rats following chlorpyrifos (CPF) 
exposure. Lethality was recorded daily and shown as the percent cumulative 
lethality after 168 hours (7 days). Rats (n = 10-20 I dosage) were treated with 
CPF (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, 110, 130, and 150 mg/kg, po) and 
graded for functional changes at 1, 2, and 4 hours and then daily for 7 days. 
LD10 estimates are based on a convergence of a sigmoidal dose-response 
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Figure 7. Cumulative lethality in 90 day-old rats following parathion (PS) 
exposure. Lethality was recorded daily and shown as the percent cumulative 
lethality after 168 hours (7 days). Rats (n = 10-20 I dosage) were treated with 
PS (0, 2, 4, 6, 8, 9, 10, 12, 15, and 18 mg/kg, po) and graded for functional 
changes at 1, 2, and 4 hours then daily for 7 days. LD10 estimates are based on 
a convergence of a sigmoidal dose-response curve, where x is the log of the 
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Figure 8. Cumulative lethality in 90 day-old rats following chlorpyrifos (CPF) 
exposure. Lethality was recorded daily and shown as the percent cumulative 
lethality after 168 hours (7 days). Rats (n = 10-20 I dosage) were treated with 
CPF (0, 120, 140, 160, 180, 200, 220, 240, 260, and 300 mg/kg, po) and graded 
for functional changes at 1, 2, and 4 hours then daily for 7 days. LD10 estimates 
are based on a convergence of a sigmoidal dose-response curve, where x is the 
log of the dose and y is the % lethality. 
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LDx PS-7 CPF-7 PS-21 CPF-21 PS-90 CPF-90 
1 0.5 8.0 1.1 23 3.9 82 
5 0.7 12 1.3 38 5.6 116 
10 0.8 15 1.5 47 6.6 136 
20 1.0 19 1.6 60 7.9 161 
30 1.1 22 1.7 70 8.8 181 
40 1.2 24 1.8 80 9.7 199 
50 1.3 27 1.9 90 11 216 
60 1.4 30 2.0 102 12 236 
70 1.5 34 2.1 116 13 259 
80 1.7 39 2.3 136 14 290 
90 2.1 49 2.5 172 17 343 
Table 3. Cumulative lethality estimates (LDx; mg/kg, po) for 7, 21, and 90 day-
old rats 7 days after parathion or chlorpyrifos. Data are represented as the 
lethality estimate calculated by Equation 1 (i.e. estimates are based on a 
convergence of a sigmoidal dose-response curve, where x is the log of the dose 
and y is the % lethality). Rows are lethal doses that cause x percent lethality 
and columns represent each pesticide given to each age group (PS-7=parathion 
in 7 day-old, PS-21=parathion in 21 day-old, PS-90=parathion in 90 day-old, 
CPF-7=chlorpyrifos in 7 day-old, CPF-21 =chlorpyrifos in 21 day-old, and CPF-
90=chlorpyrifos in 90 day-old rats). 
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Treatment Vehicle HC-3 Oxotremorine 
Vehicle 5/5 5/5 5/5 
PO 0/5 5/5 3/5 
CPO 3/5 3/5 2/5 
Table4. Survival of adult rats after oral treatment with a lethal dose of paraoxon 
(PO; 4 mg/kg) or chlorpyrifos oxon (CPO; 30 mg/kg) in peanut oil (vehicle) with 
intracerebroventricular injections of hemicholinium-3 (HC-3; 10 µg/µI given as a 
5 µI injection) or oxotremorine (4 µg/µI given as a 5 µI injection) or saline 
(vehicle). Data represent proportional survival (n=5 per treatment group). 
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Characterization of High Affinity Choline Uptake in Neonatal, Juvenile, and 
Adult Rat Frontal Cortex and Striatum 
Previous research has shown that cAMP modulates HACU in vitro and in 
vivo (Cancella et al., 1995; Vogelsberg et al., 1997). In our hands, however, we 
did not confirm these findings. Figures 9-11 show the lack of effect of various 
concentrations ( 1-1 O mM) of the membrane permeable cAMP analog, 8-bromo-
cAMP, on HACU in synaptosomes of the frontal cortex and striatum prepared 
from 7, 21, and 90 day-old frontal cortex and striatum. Forskolin-stimulated 
cAMP formation also had no effect on HACU in vitro shown in Figure 12. 
Carbachol inhibited HACU in a concentration-dependent manner in 
synaptosomes from the frontal cortex and striatum of each age group (Figures 
13-15). Oxotremorine also reduced HACU in a concentration-dependent 
manner (Figures 16-18). Carbachol and oxotremorine were both more potent in 
tissues from juvenile and adult rats compared to neonates (Figures 13-18). 
Atropine did not alter the age-related oxotremorine-induced reduction in HACU 
shown in Figures 19-21. Figures 22-24 show the concentration-dependent 
displacement of [3H]hemicholinium-3 binding by carbachol in the frontal cortex 
and striatum of neonatal.juvenile, and adult rats: ~imilarly in Figures 25-27, yet 
more effectively, oxotremorine reduced HACU in membranes from the different 
aged rat brain regions. The lack of effect of various concentrations (0.1-10,000 
µM) of the active metabolites of PS and CPF, paraoxon (PO) and chlorpyrifos 
oxon (CPO), on HACU in 7, 21, and 90 day old rat frontal cortex and striatum is 
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Figure 9. The effects of exogenously added cAMP on HACU in cortical and 
striatal synaptosomes from 7 day-old rats. 8-bromo-cAMP (1-10 mM) had no 
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Figure 10. The effects of exogenously added cAMP on HACU in cortical and 
striatal synaptosomes from 21 day-old rats. 8-bromo-cAMP (1-10 mM) had no 












20 • Cortex 




Figure 11. The effects of exogenously added cAMP on HACU in cortical and 
striatal synaptosomes from 90 day-old rats. 8-bromo-cAMP ( 1-10 mM) had no 
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Figure 12. The effects of forskolin (Forsk)-stimulated cAMP formation on HACU 
in 90 day-old cortical synaptosomes. lsobutylmethylxanthine (IBMX, 100 µM) · 
was added to inhibit phosphodiesterase degradation of cAMP. No significant 
change in HACU was detected under these conditions. Data are expressed as 
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Figure 13. The in vitro effects of carbachol on high affinity choline uptake in 
cortical and striatal synaptosomes from 7 day-old rat brain. Carbachol (1-10,000 
µM) inhibited high affinity choline uptake in a concentration-dependent manner. 
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Figure 14. The in vitro effects of carbachol on high affinity choline uptake in 
cortical and striatal synaptosomes from 21 day-old rat brain. Carbachol (1-
10,000 µM) inhibited high affinity choline uptake in concentration-dependent 
manner. The IC50 in cortex is 509 µM and striatum is 543 µM. Data are 
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Figure 15. The in vitro effects of carbachol on high affinity choline uptake in 
cortical and striatal synaptosomes from 90 day-old rat brain. Carbachol (1-
10,000 µM) inhibited high affinity choline uptake in a concentration-dependent 
manner. The IC50 in cortex is 541 µM and striatum is 528 µM. Data are 
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Figure 16. The in vitro effects of oxotremorine on high affinity choline uptake in 
cortical and striatal synaptosomes from 7 day-old rat brain. Oxotremorine (1-
10,000 µM) inhibited high affinity choline uptake in a concentration-dependent 
manner. The IC50 in cortex is 1.1 mM and striatum is 1.3 mM. Data are 
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Figure 17. The in vitro effects of oxotremorine on high affinity choline uptake in 
cortical and striatal synaptosomes from 21 day-old rat brain. Oxotremorine (1-
10,000 µM) inhibited high affinity choline uptake in a concentration-depepndent 
manner. The IC50 in cortex is 291 µM and striatum is 350 µM. Data are 
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Figure 18. The in vitro effects of oxotremorine on high affinity choline uptake in 
cortical and striatal synaptosomes from 90 day-old rat brain. Oxotremorine (1-
10,000 µM) inhibited high affinity choline uptake in a concentration-dependent 
manner. The IC50 in cortex is 211 µMand striatum is 229 µM. Data are 













Figure 19. The effects of the muscarinic antagonist atropine on oxotremorine 
inhibition of HACU in 7 day-old rat cortical and striatal synaptosomes. Atropine 
(100 µM) had no effect on oxotremorine (100 µM) induced reduction of HACU. 
Data are expressed as mean ± SE. 
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Figure 20. The effects of the muscarinic antagonist atropine on oxotremorine 
inhibition of HACU in 21 day-old rat cortical and striatal synaptosomes. Atropine 
(100 µM) had no effect on oxotremorine (100 µM) induced reduction of HACU. 
Asterisks indicate significant difference from 7 day-old tissues (Figure 19). Data 
are expressed as mean± SE. 
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Figure 21. The effects of the muscarinic antagonist atropine on oxotremorine 
inhibition of HACU in 90 day-old rat cortical and striatal synaptosomes. Atropine 
(100 µM) had no effect on oxotremorine (100 µM) induced reduction of HACU. 
Asterisks indicate significant difference from 7 day-old tissues (Figure 19) and 
pounds signs indicate significant difference from 21 day-old tissues (Figure 20). 
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Figure 22. The effects of the muscarinic agonist carbachol on 
[3H]hemicholinium-3 binding in 7 day-old rat cortical and striatal synaptosomes. 
Carbachol caused a concentration dependent displacement of 
[3H]hemicholinium-3 binding. The IC50 is 5.7 mM for cortex and 1.3 mM for 
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Figure 23. The effects of the muscarinic agonist carbachol on 
[3H]hemicholinium-3 binding in 21 day-old rat cortical and striatal synaptosomes. 
Carbachol caused a concentration-dependent displacement of 
[3H]hemicholinium-3 binding. The IC50 is 9.6 mM for cortex and 1.5 mM for 






C 80 0 
(.) 








Cortex (IC50 = 1.5 mM) 
Striatum (IC50 = 1.2 mM) 
-6 -5 -4 -3 
[Carbachol, log M] 
-2 -1 
Figure 24. The effects of the muscarinic agonist carbachol on 
[3H]hemicholinium-3 binding in 90 day-old rat cortical and striatal synaptosomes. 
Carbachol caused a concentration-dependent displacement of 
[3H]hemicholinium-3 binding. The IC50 is 1.5 mM for cortex and 1.2 mM for 
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Figure 25. The effects of the muscarinic agonist oxotremorine on 
[3H]hemicholinium-3 binding in 7 day-old rat cortical and striatal synaptosomes. 
Oxotremorine caused a concentration-dependent displacement of 
[3H]hemicholinium-3 binding. The IC50 is 2.7 mM for cortex and 1.9 mM for 
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Figure 26. The effects of the muscarinic agonist oxotremorine on 
[3H]hemicholinium-3 binding in 21 day-old rat cortical and striatal synaptosomes. 
Oxotremorine caused a concentration-dependent displacement of 
[3H]hemicholinium-3 binding. The IC50 is 831 µM for cortex and 973 µM for 







C 80 0 
(.) 









' ' ' ' ' ' ' ' ' ' ' ' ' ' ' 
' 
Cortex ( I C50 = 831 µM) ',,,',,, 
Striatum (IC50 = 580 µM) .......... ~ 
-6 -5 -4 -3 -2 
[Oxotremorine, log M] 
-1 
Figure 27. The effects of the muscarinic agonist oxotremorine on 
[3H]hemicholinium-3 binding in 90 day-old rat cortical and striatal synaptosomes. 
Oxotremorine caused a concentration-dependent displacement of 
[3H]hemicholinium-3 binding. The IC50 is 831 µM for cortex and 580 µM for 
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Figure 28. The in vitro effects of paraoxon (PO) and chlorpyrifos oxon (CPO) on 
HACU in 7 day-old rat cortical synaptosomes. There were no concentration-
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Figure 29. The in vitro effects of paraoxon (PO) and chlorpyrifos axon (CPO) on 
HACU in 7 day-old rat striatal synaptosomes. There were no concentration-
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Figure 30. The in vitro effects of paraoxon (PO) and chlorpyrifos axon (CPO) on 
HACU in 21 day-old rat cortical synaptosomes. There were no concentration-
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Figure 31. The in vitro effects of paraoxon (PO) and chlorpyrifos oxon (CPO) on 
HACU in 21 day-old rat striatal synaptosomes. There were no concentration-
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Figure 32. The in vitro effects of paraoxon (PO) and chlorpyrifos oxon (CPO) on 
HACU in 90 day-old rat cortical synaptosomes. There were no concentration-
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Figure 33. The in vitro effects of paraoxon (PO) and chlorpyrifos axon (CPO) on 
HACU in 90 day-old rat striatal synaptosomes. There were no concentration-
dependent effects by either of these toxicants on HACU. Data are expressed as 
mean± SE. 
78 
In-Vitro Effects of Paraoxon, Chlorpyrifos oxon, and Muscarinic Agonists 
on Forskolin-stimulated cAMP formation 
Figures 34-36 show inhibition of forskolin-stimulated cAMP formation by 
carbachol and oxotremorine (with/without atropine) in cortical slices from 7, 21, 
and 90 day-old rats. Inhibition by both agonists (Figure 37, oxotremorine data 
not shown) was greater in the slices from 21 and 90 day-old rats (20-26%) 
compared to tissues from the 7 day-old group (12-13%). 
PO inhibited forskolin-stimulated cAMP formation in a concentration-
dependent manner in tissues from 7, 21, and 90 day-old rats (IC50 = 52, 98, and 
191 nM; Figures 38-40). Similarly, CPO inhibited forskolin-stimulated cAMP 
-formation in slices from the three age groups (IC50 = 15, 62, and 135 nM in 
neonatal, juvenile and adult rats, respectively; Figures 41-43). The inclusion of 
atropine partially blocked the effects of PO on cAMP formation in 7 day-old 
tissues, but had no effect on PO-induced inhibition of cAMP formation in 21 or 
90 day-old tissues (Figure 44). Interestingly, atropine partially blocked the 
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Fsk Carb Carb/Atr Oxtr Oxtr/Atr 
Figure 34. The effects of the muscarinic agonists carbachol (Carb; 100 µM) and 
oxotremorine (Oxtr; 100 µM) on forskolin-stimulated (Fsk, 30 µM) cAMP 
formation in 7 day-old cortical slices. Carbachol and oxotremorine significantly 
reduced Fsk cAMP formation. This reduction was blocked by the addition of 
atropine (Atr; 10 µM). cAMP formation was calculated based on the percent 
forskolin stimulated cAMP formation in control brain slices. Asterisks indicate a 
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Fsk Carb Carb/Atr Oxtr Oxtr/Atr 
Figure 35. The effects of the muscarinic agonists carbachol (Carb; 100 µM) and 
oxotremorine (Oxtr; 100 µM) on forskolin-stimulated (Fsk, 30 µM) cAMP 
formation in 21 day-old cortical slices. Carbachol and oxotremorine significantly 
reduced Fsk cAMP formation. This reduction was blocked by the addition of 
atropine (Atr; 10 µM). cAMP formation was calculated based on the percent 
forskolin stimulated cAMP formation in control brain slices. Asterisks indicate a 
significant difference (p < 0.05) from the Fsk group. 
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Figure 36. The effects of the muscarinic agonists carbachol (Garb; 100 µM) and 
oxotremorine (Oxtr; 100 µM) on forskolin-stimulated (Fsk, 30 µM) cAMP 
formation in 90 day-old cortical slices. Carbachol and oxotremorine significantly 
reduced Fsk cAMP formation. This reduction was blocked by the addition of 
atropine (Atr; 10 µM). cAMP formation was calculated based on the percent 
forskolin stimulated cAMP formation in control brain slices. Asterisks indicate a 
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Figure 37. The age-dependent effect of carbachol (100 µM) on forskolin-
stimulated cAMP formation in 7, 21, and 90 day-old cortical slices. Carbachol 
reduced forskolin (30 µM) stimulated cAMP formation in an age-related manner. 
cAMP formation was calculated based on the percent forskolin stimulated cAMP 
formation in control brain slices. Asterisks indicate a significant difference (p < 
0.05) from the 7 day-old group. 
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Figure 38. Concentration-dependent inhibition of forskolin-stimulated cAMP 
formation by paraoxon (PO) in 7 day-old cortical brain slices. Data are 
expressed as mean % of stimulated activity ± SE. Each data point represents 
the mean ± SE of 4-5 separate experiments. The data were fitted with a 
sigmoidal dose-response curve and the IC50 was calculated as the concentration 
causing 50% blockade of the forskolin-stimulated cAMP formation (r2 = 0.89). 
Under these conditions, basal cAMP formation was 1054 ± 88 cpm/50 µI slices 
while forskolin-stimulated cAMP formation was 2986 ± 357 cpm/50 µI slices. 
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Figure 39. Concentration-dependent inhibition of forskolin-stimulated cAMP 
formation by paraoxon (PO) in 21 day-old cortical brain slices. Data are 
expressed as mean % of stimulated activity ± SE. Each data point represents 
the mean ± SE of 4-5 separate experiments. The data were fitted with a 
sigmoidal dose-response curve and the ICso was calculated as the concentration 
causing 50% blockade of the forskolin-stimulated cAMP formation (r2 = 0.92). 
Under these conditions, basal cAMP formation was 1054 ± 88 cpm/50 µI slices 
while forskolin-stimulated cAMP formation was 2986 ± 357 cpm/50 µI slices. 
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Figure 40. Concentration-dependent inhibition of forskolin-stimulated cAMP 
formation by paraoxon (PO) in 90 day-old cortical brain slices. Data are 
expressed as mean % of stimulated activity ± SE. Each data point represents 
the mean ± SE of 4-5 separate experiments. The data were fitted with a 
sigmoidal dose-response curve and the IC50 was calculated as the concentration 
causing 50% blockade of the forskolin-stimulated cAMP formation (r2 = 0.96). 
Under these conditions, basal cAMP formation was 1054 ± 88 cpm/50 µI slices 
while forskolin-stimulated cAMP formation was 2986 ± 357 cpm/50 µI slices. 
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Figure 41. Concentration-dependent inhibition of forskolin-stimulated cAMP 
formation by chlorpyrifos oxon (CPO) in 7 day-old cortical brain slices. Data are 
expressed as mean % of stimulated activity ± SE. Each data point represents 
the mean ± SE of 4-5 separate experiments. The data were fitted with a 
sigmoidal dose-response curve and the IC50 was. calculated as the concentration 
causing 50% blockade of the forskolin-stimulated cAMP formation (r2 = 0.96). 
Under these conditions, basal cAMP formation was 536 ± 108 cpm/50 µI slices 
while forskolin-stimulated cAMP formation was 2188 ± 79 cpm/50 µI slices. 
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Figure 42. Concentration-dependent inhibition of forskolin-stimulated cAMP 
formation by chlorpyrifos oxon (CPO) in 21 day-old cortical brain slices. Data 
are expressed as mean % of stimulated activity ± SE. Each .data point 
represents the mean ± SE of 4-5 separate experiments. The data were fitted 
with a sigmoidal dose-response curve and the IC50 was calculated as the 
concentration causing 50% blockade of the forskolin-stimulated cAMP formation 
(r2 = 0.99). Under these conditions, basal cAMP formation was 1054 ± 88 
cpm/50 µI slices while forskolin-stimulated cAMP formation was 2986 ± 357 
cpm/50 µI slices. 
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Figure 43. Concentration-dependent inhibition of forskolin-stimulated cAMP 
formation by chlorpyrifos oxon (CPO) in 90 day-old cortical brain slices. Data 
are expressed as mean % of stimulated activity ± SE. Each data point 
represents the mean ± SE of 4-5 separate experiments. The data were fitted 
with a sigmoidal dose-response curve and the IC50 was calculated as the 
concentration causing 50% blockade of the forskolin-stimulated cAMP formation 
(r2 = 0.93). Under these conditions, basal cAMP formation was 1054 ± 88 
cpm/50 µI slices while forskolin-stimulated cAMP formation was 2986 ± 357 
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Figure 44. The effects of atropine on PO-mediated inhibition of forskolin-
stimulated cAMP formation in cortical slices of 7, 21, and 90 day-old rats. 
Atropine (10 µM) partially blocked the inhibition of cAMP formation by PO in 
neonatal tissues, but had no apparent effect in either juvenile or adult tissues. 
Data represent the mean of five experiments ± SE. Asterisks indicate statistical 
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Figure 45. The effects of atropine on CPO-induced inhibition of forskolin-
stimulated cAMP formation in cortical slices of 7, 21, and 90 day-old rats. 
Atropine (10 µM) partially blocked the inhibition of cAMP formation by CPO in 
tissues from all three age groups. Data represent the mean of five experiments 
± SE. Asterisks indicate statistical significance (p < 0.05). 
91 
The Age- and Time-Dependent Effects of Parathion and Chlorpyrifos on 
Cholinesterase in the Frontal Cortex and Striatum of Neonatal, Juvenile, 
and Adult Rats 
ChE inhibition (65-82%) in 7, 21, and 90 day-old cortical and striatal 
synaptosomes following oral PS exposure (LD10) peaked at about 4 hours after 
exposure. ChE activity recovered to the greatest extent and in the shortest 
period of time after PS exposure in 7 day-old tissues (within 24 hours; Figures 
46 and 47), followed by 21 day~old tissues (Figures 48 and 49) 96 hours after 
treatment and lastly in 90 day-old tissues (Figures 50 and 51), which never fully 
recovered. Exposure of these age groups to the lower dosage of PS (0.5 x 
LD10) caused significant ChE inhibition (as measured in synaptosomes) only in 7 
day-old striatum (Figure 47; 4 hours after exposure), 21 day-old frontal cortex 
(Figure 48; 4 hours after exposure), and 90 day-old frontal cortex cortex (Figure 
50; 4 and 24 hours after exposure) and striatum (Figure 51; 4 hours after 
exposure). 
Oral exposure to the high dose of CPF (LD10) caused more extensive 
peak ChE inhibition (80-92%) across all the age groups compared to PS. 
However, as with PS, the time to peak inhibition after CPF exposure occurred 
early in 7 day-old tissues (Figures 52 and 53; 4 hours after exposure), but later 
in 21 and 90 day-old tissues (Figures 54-57; 24 hours after exposure). In all age 
groups and time points tested, full recovery of ChE did not occur, with the 
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Figure 46. The effects of parathion (PS; 0.4 and 0.8 mg/kg, po) on 
acetylcholinesterase (AChE) in the frontal cortex of 7 day-old rats. ChE activity 
was measured as described in methods in cortical synaptosomes at 4, 24, and 
96 hours after treatment. Data are expressed as % of control values (23.5 ± 1.2 
nmol/min/mg protein). Data represent the mean± SE (n=9-12). Asterisks 
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Figure 47. The effects of parathion (PS; 0.4 and 0.8 mg/kg, po) on 
acetylcholinesterase (AChE) in the striatum of 7 day-old rats. ChE activity was 
measured as described in methods in striatal synaptosomes at 4, 24, and 96 
hours after treatment. Data are expressed as % of control values (105.4 ± 5.0 
nmol/min/mg protein). Data represent the mean ± SE (n=9-12). Asterisks 
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Figure 48. The effects of parathion (PS; 0.75 and 1.5 mg/kg, po) on 
acetylcholinesterase (AChE) in the frontal cortex of 21 day-old rats. ChE activity 
was measured as described in methods in cortical synaptosomes at 4, 24, and 
96 hours after treatment. Data are expressed as% of control values (129.3 ± 
5.3 nmol/min/mg protein). Data represent the mean± SE (n=9-12). Asterisks 





0 100 Lo +-' 
C 






f----I ,,,,,,,,,,,'' ------------------------------------------------~ ,, 
* 
20 40 60 
Time (hours) 
___ ., __ 0.75 
• 1.5 
80 100 
Figure 49. The effects of parathion (PS; 0.75 and 1.5 mg/kg, po) on 
acetylcholinesterase (AChE) in the striatum of 21 day-old rats. ChE activity was 
measured as described in methods in striatal synaptosomes at 4, 24, and 96 
hours after treatment. Data are expressed as % of control values (226.8 ± 6.1 
nmol/min/mg protein). Data represent the mean± SE (n=9-12). Asterisks 
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Figure 50. The effects of parathion (PS; 3.3 and 6.6 mg/kg, po) on 
acetylcholinesterase (AChE) in the frontal cortex of 90 day-old rats. ChE activity 
was measured as described in methods in cortical synaptosomes at 4, 24, and 
96 hours after treatment. Data are expressed as% of control values (153.1 ± 
4.4 nmol/min/mg protein). Data represent the mean± SE (n=9-12). Asterisks 
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Figure 51. The effects of parathion (PS; 3.3 and 6.6 mg/kg, po) on 
acetylcholinesterase (AChE) in the striatum of 90 day-old rats. ChE activity was 
measured as described in methods in striatal synaptosomes at 4, 24, and 96 
hours after treatment. Data are expressed as% of control values (288.5 ± 13.2 
nmol/min/mg protein). Data represent the mean± SE (n=9-12). Asterisks 
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Figure 52. The effects of chlorpyrifos (CPF; 7.5 and 15.0 mg/kg, po) on 
acetylcholinesterase (AChE) in the frontal cortex of 7 day-old rats. ChE activity 
was measured as described in methods in cortical synaptosomes at 4, 24, and 
96 hours after treatment. Data are expressed as % of control values. (23.5 ± 1.2 
nmol/min/mg protein). Data represent the mean± SE (n=9-12). Asterisks 
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Figure 53. The effects of chlorpyrifos (CPF; 7.5 and 15.0 mg/kg, po) on 
acetylcholinesterase (AChE) in the striatum of 7 day-old rats. ChE activity was 
measured as described in methods in striatal synaptosomes at 4, 24, and 96 
hours after treatment. Data are expressed as% of control values (105.4 ± 5.0 
nmol/min/mg protein). Data represent the mean± SE (n=9-12). Asterisks 
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Figure 54. The effects of chlorpyrifos (CPF; 23.5 and 47.0 mg/kg, po) on · 
acetylcholinesterase (AChE) in the frontal cortex of 21 day-old rats. ChE activity 
was measured as described in methods in cortical synaptosomes at 4, 24, and 
96 hours after treatment. Data are expressed as% of control values (129.3 ± 
5.3 nmol/min/mg protein). Data represent the mean± SE (n=9-12). Asterisks 
























Figure 55. The effects of chlorpyrifos (CPF; 23.5 and 47.0 mg/kg, po) on 
acetylcholinesterase (AChE) in the striatum of 21 day-old rats. ChE activity was 
measured as described in methods in striatal synaptosomes at 4, 24, and 96 
hours after treatment. Data are expressed as % of control values (226.8 ± 6.1 
nmol/min/mg protein). Data represent the mean± SE (n=9-12). Asterisks 
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Figure 56. The effects of chlorpyrifos (CPF; 68 and 136 mg/kg, po) on 
acetylcholinesterase (AChE) in the frontal cortex of 90 day-old rats. ChE activity 
was measured as described in methods in cortical synaptosomes at 4, 24, and 
96 hours after treatment. Data are expressed as % of control values (153.1 ± 
4.4 nmol/min/mg protein). Data represent the mean± SE (n=9-12). Asterisks 
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Figure 57. The effects of chlorpyrifos (CPF; 68 and 136 mg/kg, po) on 
acetylcholinesterase (AChE) in the striatum of 90 day-old rats. ChE activity was 
measured as described in methods in striatal synaptosomes at 4, 24, and 96 
hours after treatment. Data are expressed as % of control values (288.5 ± 13.2 
nmol/min/mg protein). Data represent the mean.± SE (n=9-12). Asterisks 
indicate significant (p < 0.05) difference from control tissues. 
0.5 x LD10 of CPF produced significant inhibition in all the tissues tested, with the 
exception of 7 day-old cortical synaptosomes (Figure 52; 96 hours after 
exposure). Interestingly, relatively similar levels of ChE inhibition were noted 
after either 0.5 or 1 x LO of CPF in 7 day-old striatum and 21 day-old cortex and 
striatum (Figures 53, 54, and 55). 
The Age- and Time-Dependent Effects of Parathion and Chlorpyrifos on 
High Affinity Choline Uptake in the.Frontal Cortex and Striatum of 
Neonatal, Juvenile, and Adult Rats 
PS (LD10) caused an early increase (4 hours after treatment) in HACU in 
striatal synaptosomes from 7 day-old rats (52% increase; Figure 59) and 21 day-
old rats (18 and 25%; Figures 60 and 61), but at a later time point (96 hours after 
treatment). HACU was also increased later in both brain regions of 90 day-old 
rats (43 and 34%; Figures 62 and 63). Inhibition (18%) of HACU by 0.5 x LD10 
of PS was only evident in the synaptosomes from the frontal cortex of 90 day-old 
rats 96 hours after treatment (Figure 62). 
In contrast, administration of CPF orally caused reductions in HACU as 
measured in 7 day-old cortical synaptosomes (43%; Figure 64), 21 day-old rat 
cortical and striatal synaptosomes (33 and 27%; Figures 66 and 67), and 90 
day-old cortical synaptosomes (28%; Figure 68). Conversely, 7 day-old striatal 
synaptosomes exhibited an increase (11 %) in HACU 96 hours after treatment 
with the LD10 of CPF (Figure 65). There were no effects of the LD10 of CPF on 
90 day-old striatal synaptosomes (Figure 69) and 0.5 x LD10 of CPF had no 
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Figure 58. The effects of parathion (PS; 0.4 and 0.8 mg/kg, po) on high affinity 
choline uptake (HACU) in the frontal cortex of 7 day-old rats. HACU was 
measured in cortical synaptosomes at 4, 24, and 96 hours after treatment. Data 
are expressed as % of control values (2.3 ± 0.33 fmol/min/mg protein). Data 
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Figure 59. The effects of parathion (PS; 0.4 and 0.8 mg/kg, po) on high affinity 
choline uptake (HACU) in the striatum of 7 day-old rats. HACU was measured 
in striatal synaptosomes at 4, 24, and 96 hours after treatment. Data are 
expressed as % of control values (5.2 ± 1.6 fmol/min/mg protein). Data 
represenfthe mean± SE (n=9-12). Asterisks indicate significant (p < 0.05) 
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Figure 60. The effects of parathion (PS; 0. 75 and 1.5 mg/kg, po) on high affinity 
choline uptake (HACU) in the frontal cortex of 21 day-old rats. HACU was 
measured in cortical synaptosomes at 4, 24, and 96 hours after treatment. Data 
are expressed as % of control values (4.2 ± 0.3 fmol/min/mg protein). Data 
represent the mean± SE (n=9-12). Asterisks indicate significant (p < 0.05) 
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Figure 61. The effects of parathion (PS; 0.75 and 1.5 mg/kg, po) on high affinity 
choline uptake (HACU) in the striatum of 21 day-old rats. HACU was measured 
in striatal synaptosomes at 4, 24, and 96 hours after treatment. Data are 
expressed as% of control values (11.3 ± 0.7 fmol/min/mg protein). Data 
represent the mean± SE (n=9-12). Asterisks indicate significant (p < 0.05) 
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Figure 62. The effects of parathion (PS; 3.3 and 6.6 mg/kg, po) on high affinity 
choline uptake (HACU) in the frontal cortex of 90 day-old rats. HACU was 
measured in cortical synaptosomes at 4, 24, and 96 hours after treatment. Data 
are expressed as % of control values (10.6 ± 1.3 fmol/min/mg protein). Data 
represent the mean± SE (n=9-12). Asterisks indicate significant (p < 0.05) 
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Figure 63. The effects of parathion (PS; 3.3 and 6.6 mg/kg, po) on high affinity 
choline uptake (HACU) in the striatum of 90 day-old rats. HACU was measured 
in striatal synaptosomes at 4, 24, and 96 hours after treatment. Data are 
expressed as% of control values (20.9 ± 2.7 fmol/min/mg protein). Data 
represent the mean± SE (n=9-12). Asterisks indicate significant (p < 0.05) 
























Figure 64. The effects of chlorpyrifos (CPF; 7.5 and 15 mg/kg, po) on high 
affinity choline uptake (HACU) in the frontal cortex of 7 day-old rats. HACU was 
measured in cortical synaptosomes at 4, 24, and 96 hours after treatment. Data 
are expressed as % of control values (2.6 ± 0.33 fmol/min/mg protein). Data 
represent the mean± SE (n=9-12). Asterisks indicate significant (p < 0.05) 
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Figure 65. The effects of chlorpyrifos (CPF; 7.5 and 15 mg/kg, po) on high 
affinity choline uptake (HACU) in the striatum of 7 day-old rats. HACU was 
measured in striatal synaptosomes at 4, 24, and 96 hours after treatment. Data 
are expressed as % of control values (5.2 ± 1.6 fmol/min/mg protein). Data 
represent the mean± SE (n=9-12). Asterisks indicate significant (p < 0.05) 
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Figure 66. The effects of chlorpyrifos (CPF; 23.5 and 47.0 mg/kg, po) on high 
affinity choline uptake (HACU) in the frontal cortex of 21 day-old rats. HACU 
was measured in cortical synaptosomes at 4, 24, and 96 hours after treatment. 
Data are expressed as % of control values (4.2 ± 0.3 fmol/min/mg protein). Data 
represent the mean± SE (n=9-12). Asterisks indicate significant (p < 0.05) 























Figure 67. The effects of chlorpyrifos (CPF; 23.5 and 47.0 mg/kg, po) on high 
affinity choline uptake (HACU) in the striatum of 21 day-old rats. HACU was 
measured in striatal synaptosomes at 4, 24, and 96 hours after treatment. Data 
are expressed as% of control values (11.3 ± 0.7 fmol/min/mg protein). Data 
represent the mean ± SE (n=9-12). Asterisks indicate significant (p < 0.05) 




















Figure 68. The effects of chlorpyrifos (CPF; 68 and 136 mg/kg, po) on high 
affinity choline uptake (HACU) in the frontal cortex of 90 day-old rats. HACU 
was measured in cortical synaptosomes at 4, 24, and 96 hours after treatment. 
Data are expressed as % of control values (10.6 ± 1.3 fmol/min/mg protein). 
Data represent the mean± SE (n=9-12). Asterisks indicate significant (p < 0.05) 
difference from control tissues. 
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Figure 69. The effects of chlorpyrifos (CPF; 68 and 136 mg/kg, po) on high 
affinity choline uptake (HACU) in the striatum of 90 day-old rats. HACU was 
measured in striatal synaptosomes at 4, 24, and 96 hours after treatment. Data 
are expressed as% of control values (20.9 ± 2.7 fmol/min/mg protein). Data 
represent the mean± SE (n=9-12). Asterisks indicate significant (p < 0.05) 




Acute Lethality of Chlorpyrifos and Parathion in Neonatal, Juvenile, and 
Adult rats 
The tables of peak times.of lethality {Table 1) and signs of toxicity (Table 
2) show the rapid onset of toxicity following exposure to PS across age groups 
compared to CPF, which elicits toxicity earlier in younger animals. The 
differences in the peak times of lethality and signs of toxicity correspond roughly 
with the times to peak ChE inhibition with both OPs (Figures 46-57). 
PS, a highly toxic OP, was most potent in neonatal rats (LD10 = 0.8 
mg/kg), which was 2 fold more potent than for juvenile rats (LD10 = 1.5 mg/kg) 
and 8 fold more potent than in adult rats (LD10 = 6.6 mg/kg; Table 3). Age-
related differences in sensitivity to chlorpyrifos, a moderately toxic OP, showed a 
3 to 9-fold difference between neonatal (LD10 = 15 mg/kg) and juvenile (LD10 = 
47 mg/kg) rats compared to adults (LD10 = 136 mg/kg). Several other studies 
have indicated relatively similar differences in sensitivity with age with acute and 
repeated exposure to these OPs (Howard and Pope, 2002; Liu and Pope 1998; 
Chaudhuri et al., 1993; Pope and Chakraborti, 1992; Zheng et al., 2000). 
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One of the earliest studies evaluating age-and sex-related differences in 
sensitivity to OPs was published by Benke and Murphy in 1975. This study 
evaluated the effects of methyl parathion (MPS) and parathion (PS) in male and 
female rats of several different ages, ranging from 1 (newborn) to 63 (adult) days 
old. This study first demonstrated a lack of difference in sensitivity of ChE to 
methyl paraoxon and paraoxon (i.e. ChE sensitivity to inhibition by these oxons 
did not change with age nor differ between sexes). These findings suggest that 
the increase in LD50 values with increasing age was not attributable to the 
differences in sensitivity of the target enzyme for these compounds. 
Investigation of metabolic pathways found the greatest correlation between 
cytochrome P-450 mediated dearylation, A-esterase and carboxylesterase 
(binding) activity and LD50 changes, suggesting that these processes may be 
important in differential sensitivity to MPS and PS with age. 
Pope and colleagues (1991) also reported greater sensitivity of neonates 
to the acute toxicity of three organophosphorus insecticides. Developing rats (7 
days old), were 2, 9, and 6 times more sensitive than adult rats (80-100 days 
old) to subcutaneous exposure of methyl parathion, parathion, and chlorpyrifos, 
respectively. The degree of ChE inhibition between the two age groups was 
approximately the same 24 hours after maximum tolerated dosage exposure to 
all of the OPs. However, brain ChE recovered more fully in neonatal animals by 
one week after exposure. 
Other studies have also suggested an important role for detoxification 
enzymes in age-related sensitivity to organophosphorus pesticides. Atterberry 
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and associates (1997) investigated age-related changes in the sensitivity of 
target and non-target esterase activity and bioactivation enzymes towards 
parathion and chlorpyrifos. This study used several ages of rats ranging from 1-
80 days of age and measured the developmental patterns of AChE in the cortex 
and pons/medulla, and aliesterase (carboxylesterase) activity in the liver. The 
IC5o values remained constant regardless of age for paraoxon and chlorpyrifos 
axon towards the target esterase, AChE. However, dramatic differences were 
noted for IC50 values of PO and CPO towards aliesterases between young rats 
(up to 12 days old) and adult rats (80 days old). Additionally, no age-related 
differences were found in the bioactivation of either parathion or chlorpyrifos. 
These data indicated that neither the target enzyme inhibition nor the 
bioactivation of these two OPs were important in age-related differences in 
sensitivity to these compounds, but the detoxification pathway, (i.e. aliesterase), 
in the liver was most likely a contributor to the higher sensitivity of the younger 
rats. 
More recent studies (Karanth and Pope, 2000) have indicated a strong 
relationship between the age-related expression of carboxylesterase and A-
esterase activity and toxicity associated with parathion and chlorpyrifos 
exposure. Maturation aging profiles of carboxylesterase, CPO-ase, and PO-ase 
activity in plasma, liver, and lung homogenates were shown to increase 
significantly from neonatal age (7 days old) to adulthood (90 days old). 
Interestingly, plasma carboxylesterase activity declined in aged (24 months old) 
rats. There was a high correlation between the acute sensitivity to the 
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subcutaneous MTD of chlorpyrifos and the levels of esterase activity in tissues 
from each of the age groups. However, the acute sensitivity of parathion was 
only highly correlated with plasma carboxylesterase. The in vitro sensitivity of 
carboxylesterases was examined and no significant differences in IC50 values 
were noted with age. These results provide further evidence that 
maturational/aging-related changes in the levels of detoxification enzymes may 
contribute to the age-related differences in sensitivity to parathion and 
chlorpyrifos. 
These reports indicate the importance in age-related levels of specific 
detoxification enzymes for parathion and chlorpyrifos that may contribute to 
differential expression of toxicity associated with these compounds. However, 
several studies have indicated additional targets for these OPs that may also 
contribute to age-related differences in sensitivity. 
As early as 1976, in vitro studies by Muramatsu and colleagues reported 
the ability of parathion to alter some components of acetylcholine biosynthesis 
pathway (e.g. choline acetyltransferase, choline uptake). Choline 
acetyltransferase activity in crude synaptosomal preparations of whole mouse 
brain was decreased (Km= 1.81 mM), while choline uptake was 42 times more 
sensitive to inhibition by parathion (Ki= 42.7 µM). Parathion also concentration-
dependently inhibited acetylcholine synthesis in the synaptosomal fractions with 
an approximate 50% loss of ACh synthesis in the presence of 4mM parathion. 
These studies indicate the potential for the PS to disrupt neurotransmitter 
synthesis, however there are no in vitro studies to date that show significant 
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effects of paraoxon, chlorpyrifos oxon or chlorpyrifos on high affinity choline 
uptake. 
More recent in vivo studies (Liu and Pope, 1996, 1998) have indicated 
subcutaneous administration of these parent OPs, parathion and chlorpyrifos, 
can reduce HACU (15-25%) early (24-48 hours) after exposure in the frontal 
cortex and striatum of adult female rats. ACh release was also reduced in the 
striatum after parathion and chlorpyrifos exposure indicating the involvement of 
the muscarinic autoreceptor as a potential target for these OPs. Won and 
colleagues (2001) investigated the age-related effects of chlorpyrifos on 
acetylcholine release in cortical and striatal slices of rats .. There was a 
significant age-dependent increase in depolarization-stimulated ACh release 
(DSAR) between neonatal (7 day-old), juvenile (21 day-old), and adult (90 day-
old) rats. DSAR was n~t altered by carbachol or atropine in the 7 day-old 
tissues indicating the absence of muscarinic receptor autoregulation of ACh 
release at this early stage of development. However, DSAR was concentration-
dependently decreased by carbachol and increased by atropine in juvenile and 
adult tissues, with the greatest effects seen in the adult slices. Oral exposure of 
7, 21 and 90 day-old rats to chlorpyrifos (0.5 and 1 x LD10) resulted in a 
decrease in neonatal cortex (15%) at 4 hours, juvenile striatum (20%) at 96 
hours, and adult cortex(17-20%) and striatum (10-19%) at 24 hours after 
exposure. Increased DSAR was noted in juvenile striatum (37%) at 24 hours 
and adult cortex (14-39%) and striatum (12-31%) at 96 hours after exposure. 
Autoreceptor function after CPF treatment showed significant depression in 
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juvenile slices at 24 and 96 hours and adult slices at 96 hours, while no 
differences were noted in neonatal slices. Since ACh release is an essential 
step in the expression of toxicity associated with cholinesterase inhibition, these 
alterations could contribute to differences in sensitivity to acute high dose 
exposure to chlorpyrifos with age as seen in this project. To date, there are no 
studies evaluating DSAR after oral exposure to parathion under these 
conditions. 
OP modulation of ACh release was further investigated in vitro by Liu and 
coworkers (2002). In these studies, methyl paraoxon, paraoxon and chlorpyrifos 
axon were found to concentration-dependently inhibit ACh release in adult rat 
striatal slices. However, this effect was lost by the addition of a reversible 
inhibitor of AChE, meaning the ability of these axons to inhibit release was 
indirect and primarily mediated by inhibition of AChE. Direct effects on the 
autoreceptor were demonstrated at high concentrations, however. 
Regulation of HACU in Synaptosomes from the Frontal Cortex and 
Striatum of Neonatal, Juvenile, and Adult Rats 
In addition to ChE, the primary target for initiation of cholinergic toxicity, 
OPs have been shown to affect a number of other cholinergic processes 
(Mileson et al., 1998; Pope, 1999). A potential target of interest is HACU, the 
rate-limiting step in ACh synthesis. As mentioned earlier, subcutaneous 
exposure to some OPs decreases choline uptake in adult rats relatively early 
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(24-48 hours) in the time span of toxicity (2-14 days) associated with the OPs 
tested (PS and CPF; Liu and Pope, 1996; Liu and Pope, 1998). 
Little is known regarding the regulation of HACU. However, the 
ubiquitous second messenger cAMP has been reported to have a role in 
regulation of choline transport. AC is linked to muscarinic receptor activation 
through G-protein coupling. Activation of muscarinic receptors reduces cAMP 
formation (Anderson and McKinney, 1988). Some OPs have been shown to 
competitively bind to and activate subtypes of muscarinic receptors. Ward and 
coworkers (1993) investigated the relationship between the anticholinesterase 
activity of several OPs and their interaction with muscarinic receptors in cortical 
and hippocampal membranes of adult rats. Their results indicated a strong 
correlation between ChE inhibition and blockade of binding to [3H]cis-
methyldioxolane, a high affinity agonist for the M2 subtype of muscarinic 
receptors (Baker et al., 1971; Huff and Abou-Donia, 1994). Other studies have 
shown that paraoxon and chlorpyrifos oxon displace [3H]CD binding and inhibit 
cAMP formation, putatively through activation of the muscarinic receptor coupled 
to inhibition of adenylyl cyclase (Sakry et al., 1988; Jett et al., 1991; Huff et al., 
1994; Ward and Mundy, 1996). Therefore, OPs _cc;>uld potentially bind directly to 
muscarinic receptors, inhibit AC, decrease cAMP levels and ultimately decrease 
HACU. 
Additionally, OPs have been shown to phosphorylate cardiac muscarinic 
receptors of the M2 subtype (Bomser and Casida, 2001 ). Some OPs may 
phosphorylate other molecules involved in regulating cAMP levels (e.g. G-
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proteins, AC) and possibly the choline transporter itself. Phosphorylation of AC 
or the choline transporter could elicit similar effects (e.g. modulation of choline 
transport). It has been proposed that chlorpyrifos axon inhibits diacylglycerol 
lipases resulting in the activation of specific kinases normally regulated through 
extracellular stimuli, indicating the potential for this OP agent to alter intracellular 
events independent of ChE inhibition (Bomser et al., 2002). Another possible 
regulator of HACU includes PLA2, but the mechanism of how OPs may affect 
this signaling process is not well understood (Petroianu et al., 1997; Petroianu et 
al., 1999). Since the choline transporter has only recently been cloned (Okuda 
et al., 2000), not much is understood about its structure with respect to its 
regulation. However, three sites predicted to be capable of being 
phosphorylated by protein kinase C have been identified in the choline 
transporter of rats (CHT1). Two sites are on the inner loop between span 8 and 
9 and the third is on the 12th inner terminal span of amino acids of this 12 
membrane spanning protein. Considering these sites are located inside the 
cellular membrane, it is likely that the phosphorylation sites activated by second 
messenger signaling could cause conformational changes to the carrier that may 
modulate the rate of choline uptake and/or caus~ yp/down regulation of the 
transporter. We hypothesized that OPs, being capable of phosphorylation, can 
interact directly or indirectly (through AChE inhibition) with muscarinic receptors 
inhibiting adenylyl cyclase resulting in decreased cAMP formation and inhibition 
of HACU. 
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Age-Related Differences in Modulation of HACU and Inhibition of 
AChE in Cortical and Striatal Synaptosomes of Neonatal, Juvenile, and 
Adult Rats by Parathion and Chlorpyrifos 
Peak ChE inhibition (80%) occurred 4 hours after the LD10 of PS in the 
frontal cortex and striatum of neonatal, juvenile and adult rats (Figures 46-51 ). 
Maximal ChE inhibition was accompanied by an increase in HACU in neonatal 
striatum (52% at 4 hours after exposure; Figure 59) and juvenile cortex and 
striatum (19% and 23% at 4 hours after exposure; Figures 60 and 61 ), but 
increases in HACU occurred later in adult cortex and striatum (41 % and 36% at 
96 hours after exposure; Figures 62 and 63). 
Equitoxic dosages of CPF also elicited relatively similar maximal 
reductions (>80%) of cortical and striatal ChE with peak inhibition occurring 
earlier in neonatal and juvenile (4 hours after exposure; Figures 52-55) than in 
adult (24 hours after exposure; Figures 56 and 57) rats. HACU was reduced 
(43% at 4 hours after exposure) in neonatal cortex (Figure 64) with no change in 
neonatal striatum (Figure 65). However, HACU in the cortex and striatum of 
juvenile rats (Figures 66 and 67) was reduced (17-22% at 24 hours after 
exposure). In adults, only cortical HACU was reduced (19% at 96 hours; 
Figures 68 and 69). 
Several studies have reported that some OP toxicants directly inhibit 
cAMP formation, and cAMP has been reported to modulate HACU. Such a 
direct action could occur independent of AChE inhibition and thus, such changes 
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in HACU could theoretically modify the toxicity of AChE inhibition. If HACU was 
reduced prior to peak AChE inhibition, this could ultimately limit the activation of 
postsynaptic receptors. Alternatively, an early increase in HACU could augment 
the toxicity resulting from extensive ChE inhibition by increasing the availability 
of ACh to be released and accumulate in the synapse. While the younger 
animals may suffer this fate, the later increases in adults may have lesser 
consequences on the expression of toxicity. In no case did changes in HACU 
precede inhibition of AChE. 
As HACU is an activity dependent process (i.e. 1increased cholinergic 
neurotransmission leads to increased HACU), changes in HACU could reflect 
coordinate changes in neuronal activity. With accumulation of ACh, subsequent 
blockade of postsynaptic activity could occur with feedback regulation of the 
presynaptic neurons. Furthermore, an increase/reduction in HACU/ACh 
synthesis, while it could potentially modify the toxic effects of AChE inhibition, 
could also lead to qualitative differences in response to immature and adult rats 
due to the additional role of ACh in development. 
Together these results suggest that brain HACU and ACh synthesis may 
be affected by high-dose PS or CPF exposure in neonatal, juvenile, and adult 
rats. Due to possible differences in physiological roles of ACh during maturation 
and adulthood, and the time-dependency of HACU changes, these effects could 
contribute to qualitative and quantitative differences in sensitivity to PS and CPF. 
In summary, regulation of HACU, although previously reports indicate 
cAMP to be involved, remains elusive. In spite of the lack of effects of paraoxon 
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and chlorpyrifos oxon on HACU in vitro, muscarinic agonists can directly 
interfere with choline transport and reduce HACU in neonatal, juvenile, and adult 
tissues. Inhibition of cAMP formation in cortical slices by PO and CPO was age-
dependent and most potent in neonates at relatively similar concentrations seen 
with AChE inhibition, indicating a physiologically relevant alternative target. 
Cortical slices, as opposed to synaptosomes, may contain the apparatus 
necessary to examine changes in HACU along with the changes in cAMP levels 
and better define the role of cAMP in the regulation of choline uptake. The age-
and time-dependent in vivo modulation of HACU by PS or CPF exposure reveals 
distinctly different mechanisms that may contribute to greater toxicity with PS, 
due to the increase in HACU that could translate into greater concentrations of 
ACh in the synapse, or lesser toxicity with CPF, due to the decrease in HACU 
may reduce the levels of ACh released into the synapse. However, it is difficult 
to determine the extent of the effect of a 50% increase or decrease in HACU at 
specific times on ACh levels without measuring ACh in the synapse. 
Comparatively, studies have administered hemicholinium-3 at doses causing 
inhibition of HACU in adult rats and noticed reductions in ACh synthesis and 
release thus CPF could have a similar effect. Other studies have indicated 
administering compounds that are known to increase HACU result in an 
increase in ACh synthesis and release thus the potential for PS exposure to 
have a similar effect. 
Overall, the modifications of HACU activity in the adult rats appear to 
occur to late to alter the toxicity associated with extensive AChE inhibition. 
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However, the changes in neonatal rats coincide with peak AChE inhibition and 
thus would potentially increase the toxicity associated with PS or CPF exposure. 
The increase in HACU after PS exposure may result in an increase in ACh 
synthesis and release into the synapse thus worsening the toxicity. In contrast, 
the decrease in HACU associated with CPF exposure may decrease the levels 
of ACh in the synapse and potentially reduce the toxicity of this OP. However, 
studies examining the effects of HC-3 administration noted similar signs and 
symptoms of toxicity as seen with OP exposure indicating the potential for CPF 
reductions in HACU to result in greater toxicity. Taken together, PS and CPF 
have both been shown in this study to significantly alter HACU with age and over 
time and their axons to affect alternative targets at physiologically relevant and 
primary target comparable concentrations. 
We then evaluated the in vitro effects of cAMP on HACU. In our hands, 
HACU in crude synaptosomes prepared from neonatal, juvenile, and adult rat 
frontal cortex and striatum was unaffected by the addition of a wide range of 
cAMP concentrations (Figures 9-11) or forskolin stimulated cAMP (Figure 12). 
Several factors may have contributed to the lack of effects of cAMP on HACU 
including the purity of the synaptosomal preparation or the loss of an important 
element of the cAMP pathway during tissue preparation. In contrast, muscarinic 
agonists significantly reduced choline uptake in these same synaptosomal 
preparations (Figures 13-18). Carbachol caused concentration-dependent 
inhibition of HACU in cortical and striatal synaptosomes in each of the age 
groups tested indicating some linkage between muscarinic agonists and choline 
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transport (Figures 13-15). Similar to carbachol, yet more potent, oxotremorine 
inhibited HACU in a concentration-dependent manner in synaptosomes from the 
frontal cortex and striatum of 7 (affected minimally), 21 (affected moderately), 
and 90 (affected maximally) day-old rats (Figures 16-18) and was not sensitive 
to blockade by atropine (Figures 19-21). 
Molecules that interact with the choline transporter generally have a 
quaternary nitrogen and a free hydroxyl group. These characteristics are seen 
with the structures of choline, hemicholinium-3 (a highly specific inhibitor of 
choline transport; Happe and Murrin, 1993; Manaker et al., 1986), and several 
derivatives of HC-3 (Bhattacharyya et al., 1987; Chatterjee et al., 1987; Cannon 
et al., 1994; Sterling et al., 1986). Both carbachol and oxotremorine partially 
meet these requirements (Taylor, 1990) and therefore could interact directly with 
the transporter. Other studies by Kotas and Prince (1987) reported that the 
choline transporter had a lower affinity towards choline in the developing rat 
hippocampus and cortex. In addition to reinforcing the understood rate-limiting 
step of ACh synthesis as choline uptake, this study shows the greatest 
sensitivity of choline transport to hemicholinium-3 (1 µM) in adult brain, followed 
by juvenile (12-14 days old), and lowest in neonatal (4-8 days old) 
synaptosomes. These results may partially explain the age-related increase in 
sensitivity to agonists that interact directly with the choline transporter. 
There was an age-related difference in the ability of carbachol to inhibit 
HACU that may be a reflection of the number of choline transporters present, 
(Shelton et al., 1979), the choline selectivity of the transporter in younger 
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animals, and possibly the density of muscarinic receptors that can interact with 
carbachol if cAMP regulates HACU. In these studies, the possibility of the 
number of transporters influencing carbachol and oxotremorine inhibition of 
HACU across the age groups is controlled for by expressing the data as percent 
of control. Specific recognition of choline or compounds structurally similar to 
choline, like carbachol and oxotremorine, could play a role in decreasing choline 
transport, considering the rate of uptake of choline increases earlier than the 
number of transporters during maturation (Shelton et al., 1979). Lastly, the 
indirect effects of these two muscarinic agonists, inhibition of adenylyl cyclase 
and decreased cAMP formation, would be a reasonable consideration with the 
low density of muscarinic receptors available in the younger animals, which has 
been previously shown to increase dramatically during maturation (Disko et al., 
1999; Kuhar et al., 1980). 
Displacement of [3H]HC-3 studies revealed the interaction of carbachol 
and oxotremorine directly with the choline transporter of neonatal, juvenile, and 
adult cortical and striatal synaptosomes (Figures 22-27). While the approximate 
IC50s of carbachol and oxotremorine towards [3H]HC-3 displacement are several 
fold higher than those that inhibit HACU, these d_iscrepancies could be due to 
the different tissue preparations and assay conditions. The direct interaction 
may only partially explain the inhibition of choline transport, e.g. agonism of the 
muscarinic receptor may contribute to differences in the IC5as between the two 
assays. 
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Neither paraoxon (PO) nor chlorpyrifos axon (CPO) affected the rate of 
choline uptake in cortical or striatal synaptosomes from neonatal, juvenile and 
adult rats (Figure 28-33). Similar results have been shown in earlier work from 
our laboratory (Liu and Pope, 1996). This lack of effect could be due to the lack 
of a specific component that is lost in the preparation of synaptosomes or that 
the axons are indirectly responsible for decreases in HACU through 
acetylcholinesterase inhibition. 
Forskolin-Stimulated cAMP Formation as Affected by PO, CPO and 
Muscarinic agonist in Neonatal, Juvenile; and Adult Tissues 
Characterization of the effects of muscarinic agonists, carbachol and 
oxotremorine, in cortical slices from neonatal, juvenile, and adult rats (Figures 
34'."36) shows a definitive reduction in forskolin (FSK) -stimulated production of 
cAMP across ages. Atropine (a muscarinic receptor antagonist) was added to 
demonstrate muscarinic receptor involvement and completely blocked the 
effects of carbachol and oxotremorine in all of the age groups. The greatest 
reduction in FSK-stimulated cAMP formation (20:-25%) was seen in the adult and 
juvenile tissues compared to neonatal slices (12%; Figure 37) possibly due to 
the increase in muscarinic receptor density with maturation (Coyle and 
Yamamura, 1976; van Huizen et al., 1994; Aubert et al., 1996; Tice et al., 1996). 
Although carbachol and oxotremorine produced age-related reductions in 
cAMP formation, PO and CPO produced relatively similar reductions with 
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different age tissues (Olivier et al., 2001 ). In contrast, neonatal tissues (Figures 
38 and 41) were more sensitive to inhibition of FSK-stimulated cAMP formation 
by both PO (ICso = 52 nM) and CPO (ICso = 15 nM), followed by juvenile tissues 
(Figures 39 and 42; PO IC50 = 98 nM; CPO IC50 = 62 nM), with the least 
sensitive tissues being from adult rats (Figures 40 and 43; PO IC50 = 191 nM; 
CPO IC50 = 135 nM). The concentrations of axons capable of reducing cAMP 
formation are relatively similar to reported ICso values for these toxicants 
towards brain AChE (2-43 nM; Benke and Murphy, 1975; Atterberry et al., 1997; 
Mortensen et al., 1998). Atropine (10 µM) partially blocked CPO-mediated 
inhibition of FSK-stimulated cAMP formation in all tissues tested, while partially 
blocking PO-mediated inhibition only in neonatal tissues (Figures 44 and 45). 
The axons lack of or partial sensitivity to atropine suggests OP-induced 
modulation of FSK-stimulated cAMP formation may occur through receptor-
dependent and independent mechanisms. · 
Several studies have indicated various degrees of atropine blockade of 
the inhibitory actions of PO and CPO towards stimulated cAMP formation. PO 
inhibition of FSK-stimulated cAMP formation was completely sensitive to 
atropine blockade iri striatal cells and cortical sli~ei; (Jett et al., 1991; Ward and 
Mundy, 1996). In contrast, the effects of CPO have been reported to be only 
partially sensitive (Ward and Mundy, 1996) in cortical slices or completely 
atropine resistant (Huff et al., 1994) in striatal slices. Additional research has 
indicated exposure of neonates to CPF caused disruption in the AC cascade 
including expression of AC, G-proteins, and neurotransmitter receptors coupled 
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to inhibition of AC (Song et al., 1997). These multiple sites of interactions of 
OPs with various components of the cAMP cascade require further investigation. 
Recent evidence has identified the ability of OPs to displace [3H]cis-
dioxolane, a highly selective muscarinic agonist (Huff et al., 1994; Ward and 
Mundy, 1996). Interaction with the muscarinic receptor subtypes responsible for 
inhibition of AC could explain the differences in cAMP production seen between 
the age groups. As noted above, Bomser and Casida (2001) reported that CPO 
diethylphosphorylated the M2 subtype of muscarinic receptor in rat cardiac 
membranes. [3H]CPO labeling of rat cardiac M2 muscarinic receptors was not 
sensitive to oxotremorine. These studies may explain why atropine only partially 
blocks the effects of CPO inhibition of FSK-stimulated cAMP formation in that 
CPO binds to a site distinct but coupled to the actual agonist/antagonist binding 
site, which may be the case for PO as well. 
AC levels have been reported to be low in postnatally developing animals 
relative to the mature adult brain (Araki et al., 1995). However, isoforms of AC 
undergo differential levels of expression during development. For example, type 
I measured in the cortex of rats and mice decreases with maturation, whereas 
this same type increasesin the hippocampus (M_atsuoka et al., 1997; Villacres et 
al., 1995). Other isoforms have also been indicated to undergo this age-related 
modulation of expression in other brain regions (Matsuoka et al., 1997; Defer et 
al., 1995). The neonatal rats in our studies exhibited greater stimulation of FSK-
stimulated cAMP formation compared to the adults, possibly due to the 
differential expression of AC isoforms in the regions examined. These 
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differences in the expression of AC isoforms could explain the greater potency of 
PO and CPO towards inhibition of FSK-stimulated cAMP formation. These data 
indicate the potential for OPs to modulate second messenger systems involved 
in a plethora of cellular functions that ultimately could contribute to age-related 




1. Neonatal (7 day-old) rats were up to 9 times more sensitive and juveniles 
up to 4 times more sensitive to PS and CPF lethality than adults. 
2. Equi-toxic dosages of PS and CPF elicited age- and time-dependent 
differences in toxicity and lethality with similar levels of inhibition of AChE 
among age groups, suggesting additional sites of action. 
3. Modulation of HACU was age-, time-, dose-, and OP-dependent, 
suggesting OP-induced regulation of HACU contributes to differential 
toxicity. 
4. Previous reports indicated cAMP involvement in the regulation of HACU, 
but in our hands exogenous or endogenous cAMP had no apparent effect 
on HACU. However, muscarinic agonists.reduced HACU, apparently 
through direct interaction with the choline transporter and not through 
. muscarinic receptor-mediated inhibition of cAMP formation. 
5. PO and CPO age- and concentration-dependently inhibited forskolin-
stimulated cAMP formation through muscarinic receptor dependent and 
independent mechanisms in 7, 21 and 90 day-old rat cortical slices, but 
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had no effect on synaptosomal HACU in vitro. The mechanism for 
alteration of HACU in vivo by these OPs is unclear. 
6. lntracerebroventricular injection of the HACU inhibitor, hemicholinium-3, 
protected against the lethality of acute oral PO (LD100), but not CPO. This 
suggests a greater role of HACU in PO toxicity under these conditions. 
7. Increases in HACU following PS exposure coincided with peak AChE 
inhibition in neonatal and juvenile rats, but occurred later in adults. This 
difference in timing of changes in HACU could affect differentially the 
synthesis and accumulation of ACh in the synapses·of younger rats, 
possibly resulting in greater toxicity. 
8. In comparison, peak AChE inhibition after CPF exposure occurred 
simultaneously with reductions in HACU in neonatal and juvenile rats, but 
sequentially in adults indicating the potential for less synthesis and 
release of ACh in the synapse of the younger groups. 
9. Age-related changes in brain HACU by PS and CPF may contribute to 
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